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What's new? 
Previous genome-wide association studies identified rs13281615 and rs11780156 on 8q24 as 
breast cancer susceptibility loci. The authors performed a fine-mapping study including 55,540 
breast cancer cases and 51,168 controls within the Breast Cancer Association Consortium and 
identified three additional, represented by rs35961416, rs7815245, and rs2033101, respectively. 





Previous genome-wide association studies among women of European ancestry identified two 
independent breast cancer susceptibility loci represented by single nucleotide polymorphisms 
(SNPs) rs13281615 and rs11780156 at 8q24. We conducted a fine-mapping study across 2.06 
Mb (chr8:127,561,724 -129,624,067, hg19) in 55,540 breast cancer cases and 51,168 controls 
within the Breast Cancer Association Consortium. We found three additional independent 
association signals in women of European ancestry, represented by rs35961416 (OR = 0.95, 95% 
CI = 0.93-0.97, conditional P = 5.8 × 10
-6
), rs7815245 (OR = 0.94, 95% CI = 0.91-0.96, 
conditional P = 1.1 × 10
-6
), and rs2033101 (OR = 1.05, 95% CI = 1.02-1.07, conditional P = 1.1 
× 10
-4
). Integrative analysis using functional genomic data from the Roadmap Epigenomics, the 
Encyclopedia of DNA Elements project, the Cancer Genome Atlas, and other public resources 
implied that SNPs rs7815245 in Signal 3, and rs1121948 in Signal 5 (in linkage disequilibrium 
with rs11780156, r
2
 = 0.77), were putatively functional variants for two of the five independent 
association signals. Our results highlight multiple 8q24 variants associated with breast cancer 






Breast cancer is one of the most common malignancies among women worldwide.
1
 Genome-
wide association studies (GWASs) have identified approximately 100 loci associated with breast 
2
cancer.  Multiple independent variants on 8q24 have been shown to confer susceptibility for 
3,4
multiple types of cancer, including breast,  prostate, colorectal, bladder, ovarian, renal cell, 
5
glioma, chronic lymphocytic leukemia, and Hodgkin’s lymphoma,  (also see Supplementary 
Figure S1). Although most of these loci are located in a “gene desert” region, several hundred 
kilobases (kb) telomeric to several genes including FAM84B, POU5F1B, MYC, and the long 
non-coding gene PVT1. A growing number of studies have shown that the 8q24 locus may 
harbor long-range regulatory elements involved in regulating expression of the MYC
6
  or PVT1 
7
genes.  
 In most GWAS, only the single nucleotide polymorphism (SNP) showing the strongest 
statistical association at each locus (hereinafter referred to as the index SNP) is reported. Those 
index SNPs themselves are usually not the causal variants but are in linkage disequilibrium (LD) 
with the functional variants. In addition to the common variants identified by GWAS, low-
8
frequency variants in susceptible loci may also be associated with disease risk.  Furthermore, in 
each locus, there may exist allelic heterogeneity and multiple independent variants that may be 
8
associated with complex diseases.  Some of the missing heritability for disease may be derived 
from the incomplete coverage of genetic variants and poor representation of the full spectrum of 
9,10
causal variants on commercial genotyping arrays.  Therefore, it is necessary to conduct fine-
scale mapping studies to investigate comprehensively all genetic variants in the LD blocks where 




 We conducted a fine-mapping study of the 8q24 region using data from 106,708 
individuals within the Breast Cancer Association Consortium (BCAC). We systematically 
evaluated the associations with breast cancer risk of the SNPs across 2.06 Mb in this 
chromosome region. We aimed to identify additional independent association signals and 
potentially functional variants that may be responsible for the observed associations of variants 
in this locus with breast cancer risk.   
 
Materials and Methods 
Ethics statement 
All studies were approved by the relevant institutional review committee and informed consent 
was obtained from all participants. 
 
Subjects 
Epidemiological and genotype data were obtained from 50 breast cancer case-control studies 
4
participating in the BCAC.  The sample set for the current project included 48,155 cases and 
43,612 controls of European ancestry from 39 studies, 6,269 cases and 6,624 controls of Asian 
ancestry from 9 studies, and 1,116 cases and 932 controls of African ancestry from 2 studies. 
The estrogen receptor (ER) status of the primary tumor was available for 35,824 cases of 





SNP selection and genotyping 
Fine-mapping SNPs were selected for inclusion on the custom Illumina iSelect array 
4,11–13
(iCOGS),  with the following criteria: 1) Defining the interval to include all SNPs with r
2 
> 
0.1 with the index SNPs rs13281615 and rs11780156 based on HapMap 2 CEU, which identified 
a region of 2.06 Mb (base positions 127,561,724 -129,624,067; NCBI build 37 assembly); 2) 
Identifying all SNPs in the interval using the 1000 Genomes Project CEU (April 2010), and 
HapMap 3; 3) Selecting high-quality SNPs: only variants with the minor allele called at least 
twice in the 1000 Genomes Project and an Illumina designability score > 0.8 were included; 4) 
Selecting all SNPs with r
2
 > 0.1 with the index SNPs rs13281615 and rs11780156 from the CEU 
data set of the 1000 Genomes Project or HapMap 3; 5) Selecting tagging SNPs at r
2 
> 0.9 to 
capture the remaining SNPs that are not in LD with the index SNPs (r
2
 < 0.1). Genotyping of the 
iCOGS array and details of the genotyping calling and quality control has been described 
4,11,12
elsewhere.  In order to improve SNP density and imputation quality, we conducted one-step 
imputation (without phasing) using the program IMPUTE2 (see URLs) with the March 2012 
release of the 1000 Genomes Project as reference. Genotypes were successfully imputed for 
10,593 variants in samples of European ancestry, 9,218 variants in samples of Asian ancestry, 
and 17,964 variants in samples of African ancestry, all with imputation-r
2
 > 0.3. After excluding 
SNPs with minor allele frequency (MAF) < 0.02, the final genotype data in this project included 
6,631 SNPs in samples of European ancestry, 6,459 SNPs in samples of Asian ancestry, and 






The per-allele odds ratio (OR) and 95% confidence interval (CI) for each SNP was estimated for 
breast cancer risk using a log-additive logistic model with covariates of study site and principal 
components (PC; eight PCs with one additional principal component from the LMBC study in 
Europeans, two PCs in Asians and two in African Americans). Per-allele ORs and CIs were 
estimated separately for each population for overall disease, for ER+ and for ER- breast cancer. 
To identify potential independent susceptibility variant(s), stepwise forward logistic regression 
analyses were employed with or without the index SNPs rs13281615 and rs11780156 forced in 
the model. SNPs with a P value < 10
-4
 from the single variant analysis were included in this 
11
analysis.  To identify potentially functional variant candidate(s), we computed a likelihood ratio 
for each SNP relative to the representative SNP in each signal and excluded SNPs with a 
likelihood ratio < 0.01. Because no SNPs showed P < 1×10
-4
 in Asian or African ancestry data, 
such analyses were performed only on data from subjects of European ancestry. We used the 
haplo.stats package in R for haplotype analyses for the SNPs that are independently associated 
with breast cancer risk in women of European ancestry, with study sites and principal 
components as covariates. The familial relative risk (FRR) was estimated with the formula 
ln(λ)/ln(λo), where λ is the FRR to offspring of an affected individual due to a single genetic 
locus or assumed multiplicatively interacting loci and λo is the overall FRR, which was assumed 
14
to be 1.8 for breast cancer.  All analyses were conducted using R version 3.0.1. 
 
Functional annotation 
We annotated a total of 245 breast cancer risk associated variants (P<10
-4
 from univariate 
analysis) for potential functional significance using data from the Encyclopedia of DNA 




Genome Atlas (TCGA) (see URLs). For each variant, we investigated whether it is mapped to 
transcriptional elements primarily associated with enhancers (H3K4me1) or promoters 
(H3K4me3), in any of nine cell lines: normal human mammary epithelial cell line (HMEC), 
GM12878, H1-hESC, K562, HepG2, HSMM, HUVEC, NHEK, and NHLF. The epigenetic 
landscape of histone markers H3K4Me1, H3K4Me3, and H3K27Ac was also examined through 
layered histone tracks on seven ENCODE cell lines, including GM12878, H1-hESC, K562, 
HSMM, HUVEC, NHEK, and NHLF from the UCSC Genome Browser (see URLs). DNase I 
hypersensitive and transcription factor (TF) ChIP-Seq datasets were investigated in all available 
ENCODE cell lines, including HMEC and the breast cancer cell lines T-47D and MCF-7. 
15 16
Publicly available tools RegulomeDB  and HaploReg v4.1  were also used to evaluate potential 
functional variants. 
        For regions lacking ChIP-seq peaks data, we collected raw ChIP-seq data for the estrogen 
receptor-α (ESR1) and forkhead box protein A1 (FOXA1) in MCF-7, TAMR and ZR751 breast 
cancer cell lines (Supplementary Table S1) from the study by Hurtado et al.
17
  The raw ChIP-seq 
data in .FASTQ format from different lanes in the same experiment were first merged and 
18
mapped to the human reference genome (hg19) using the Bowtie2 program  with the default 
setting. Aligned data were processed and converted into Binary Sequence Alignment/Map format 
19
(BAM) files using the SAMtools program.  After removing duplicated reads, we used the 
20
MACS14 (version 1.4.2) algorithm  to identify peaks with 50 bp resolution using the matched 
DNA input data as the control. The peaks were ranked by the number of uniquely aligned reads 
and only the top 5% of peaks were selected for motif discovery. The summits of the top 5% 
peaks were extended by 100 bp on either side. Similar methodological strategy has been used 
21,22





employed the MEME 4.9.1 toolkit  to search DNA motifs and enrichment significance for 
ESR1 and FOXA1. 
 
Expression quantitative trait (eQTL) analysis 
24
eQTL analysis was performed followings the method described previously.  Briefly, RNA-Seq 
V2 data (level 3) of 1,006 breast cancer tumor tissues were downloaded from the TCGA data 
portal (see URLs). DNA methylation data measured by the Illumina HumanMethylation450 
BeadChip and genotype data from the Affymetrix SNP 6.0 array were also retrieved from TCGA 
level 3 data. Genotype data of the flanking 2 Mb region of the index SNPs on 8q24 were 
extracted and then imputed to the 1000 Genomes Project data with Minimac (see URLs). Only 
common SNPs (MAF > 0.05) with high imputation quality (r
2
 > 0.3) were included in the present 
study. For the interrogated 2 Mb region, copy number variation (CNV) data spanning the 8q24 
genes FAM84B, POU5F1B, MYC, and PVT1 from TCGA tumor tissue samples were collected 
from the CbioPortal (see URLs).   
        We used the TCGA breast cancer data described above to perform cis-eQTL analyses in 
tumor tissues. Several steps were taken to reduce the batch and other technical effects on gene 
25
expressions following the approach described by Pickrell et al.  First, the RNA-Seq by 
Expectation-Maximization value of each gene was log2 transformed and genes with a median 
expression level of 0 across tissues were removed. We then performed the principal component 
correction on gene expression to remove potential batch effects. A linear regression of 
expression values on the first five principal components was constructed and the residuals were 
used to replace the expression values of each gene among tissues. To make the data more closely 




levels to fit quantiles of N(0,1) distribution based on the ranks of the expression values to their 
respective quantiles. Finally, to further adjust for the potential effects of methylation and CNV 
on the expression of each gene in tumor tissues, we constructed residual linear regression models 
26
to detect eQTLs according to the approach used by Li et al.  
 
Results 
Associations with breast cancer risk among women of European ancestry 
We first conducted univariate analysis for 2,391 genotyped and 4,240 well-imputed SNPs in 
samples from women of European ancestry. A total of 359 SNPs were associated with breast 
cancer risk with a statistical significance of P < 10-4 (Figure 1 and Supplementary Table S2). 
Confirming previous GWAS results, the index SNPs rs13281615 (Signal 2 in Table 1) and 
rs11780156 (Signal 5 in Table 1) showed significant associations with ORs of 1.11 (95% CI = 
1.08-1.13, P = 2.0 × 10
-24
) and 1.07 (95% CI = 1.05-1.10, P = 4.1 × 10
-8
), respectively (Table 1, 
univariate analysis). We then conducted forward stepwise regression analysis for each of the 359 
SNPs to identify potential independent association signals. When two index SNPs rs13281615 
and rs11780156 were forced into the model, we found two additional independent association 
signals at statistical significance of P < 1 × 10
-4
 and a third one with suggestive evidence (P = 
1.1× 10
-4
) (Table 1 and Supplementary Figure S2). The first independent signal (Signal 1 in 
Table 1), represented by rs35961416 (chr8:128213561:I) with an insertion of base A, showed a P 
value of 5.8 × 10
-6
 after adjustment for other four signals (conditional OR = 0.95, 95% CI = 
0.93-0.97). The second independent signal (Signal 3) represented by rs7815245 (conditional OR 
= 0.94, 95% CI = 0.91-0.96, P = 1.1 × 10
-6




rs13281615 in Signal 2 (r
2
 = 0.48) but not with the second index SNP rs11780156 in Signal 5 (r
2
 
< 0.01). The third suggestive independent variant (Signal 4, rs2033101), not in LD with either of 
the two index SNPs, showed a conditional P value of 1.1 × 10
-4
 (OR = 1.05, 95% CI = 1.02-1.07, 
Table 1). We also performed forward stepwise regression analysis without the two index SNPs 
forced into the model. Five similar independent breast cancer risk associated SNPs were selected: 
Signal 1 (rs35961416) (conditional P = 3.2 × 10
-6
) and the suggestive Signal 4 (rs2033101) 
(conditional P = 1.4 × 10
-4
) remained the same; Signal 2 (rs13281615) was tagged by the highly 
correlated SNP rs10110330 (r
2
 = 0.97, conditional OR = 1.06, 95% CI = 1.04-1.09, P = 9.5 × 10
-
6
), Signal 3 (rs7815245) tagged by the most significant SNP rs17465052 (r
2
 = 0.93, conditional 
OR = 0.94, 95% CI = 0.91-0.97, P = 3.2 × 10
-6
), and Signal 5 (rs11780156) tagged by 
c8_pos129263191 (rs67397162, r
2
 = 1, conditional OR = 1.07, 95% CI = 1.05-1.10, P = 1.1 × 
10
-7
). These results consistently showed four independent risk association signals and another 
suggestive one (Supplementary Figure S2). No significant evidence of between-study 
heterogeneity was observed for any of these independently risk-associated SNPs (data not 
shown). 
 Stratified by ER status, all five independent signals showed significant associations for 
ER+ breast cancer; however, with the exception of rs11780156 showing a P value of 0.012 
(signal 5), no significant associations were observed for ER- breast cancer (Table 2).  
        Haplotype analyses were performed using data from the five independent risk signals (Table 
3). In women of European ancestry, a total of 16 haplotypes with frequency of > 1% were 
observed. Compared to the reference haplotype, which carries the alleles associated with a 
reduced risk in all five SNPs, most haplotypes were associated with increased breast cancer risk. 




significant association (P = 3.4 × 10
-11
 for overall breast cancer) while Haplotype 1, which 
carries the risk-associated alleles of all signals except for Signal 4, was associated with the 
highest estimated OR (OR = 1.27, 95% CI = 1.15-1.39 for overall breast cancer) (Table 3). As 
shown in Table 3, similar haplotype associations were observed for ER+ but not for ER- breast 
cancer.  
 
Association with breast cancer risk in women of Asian or African ancestry 
Of the five independently risk-associated variants identified in women of European ancestry, 
only rs35961416 (Signal 1) showed a nominal association in African-American women at P < 
0.05 (P = 0.04, Table 4). Based on univariate analyses of all SNPs on 8q24 that passed QC, SNP 
rs76382129 showed a P value of 8.3 × 10
-4 
in women of Asian ancestry and five SNPs showed P 
values of between 9.6 × 10
-4
 and 1.6 × 10
-4 
in women of African ancestry (Supplementary Table 
S3). Another 16 SNPs showed breast cancer risk association with P values between 0.01 and 
0.001 in either population and in the same direction across the two populations (Table 4). 
 
Functional annotation 
For each of the five independent signals identified among women of European ancestry, we 
excluded SNPs with r
2
 ≤ 0.2 with the representative SNP in each signal region and then 
calculated the likelihood of all risk-associated variants to select potentially functional variant 
candidates. Setting a likelihood ratio threshold of > 0.01 relative to the representative/index SNP 




(Signal 1) and rs2033101 (Signal 4) whereas we identified 154 functional variant candidates for 
Signal 2, 170 variants for Signal 3 (143 variants overlap with those for Signal 2), and 62 variants 
for Signal 5, respectively (Supplementary Tables S4-S6). Thus, a total of 245 unique SNPs 
including the five representative SNPs in five signal regions were further evaluated for their 
potentially functional significance.  
        Our integrative functional annotation from ENCODE, Roadmap Epigenomics, the 
15 16
RegulomeDB , the HaploReg databases , and other public data identified the representative 
SNP rs7815245 in Signal 3 and SNP rs1121948 (in LD with rs11780156) in Signal 5 as most 
likely functional variant candidates underlying respective independent association signals 
(Figure 2).  Based on the Roadmap Epigenomics data, SNP rs7815245 in Signal 3 is mapped to a 
conserved enhancer region with a genomic evolutionary rate profiling (GERP) score of 5.04 
among eight tissues including breast variant human mammary epithelial cells (vHMEC) and 
breast myoepithelial primary cells. It is in a DNase I hypersensitive region in eight tissues 
including vHMEC. It is also predicted to change the transcription factor TCF12 binding motif.  
This SNP  is also located in the binding regions of two critical nuclear hormone responsible 
receptors, estrogen receptor-α (ESR1), and forkhead box protein A1 (FOXA1) (Supplementary 
Figure S3). ChIP-seq data from different breast cancer cell lines and technical replicates showed 
consistent results (Supplementary Figure S3A). DNA binding motif analysis further confirmed 
that SNP rs7815245 is located in the ESR1 DNA binding motif (P = 1.5 × 10
-3
) and is very close 
to the FOXA1 DNA binding motif (P = 5.2 × 10
-3
) (Supplementary Figure S3B). In addition, the 
breast cancer risk-associated T allele was correlated with decreased expression of the POU5F1B 




SNP rs1121948, which is in strong LD with the index SNP rs11780156 (r
2
=0.77) in 
Signal 5, resides in the binding motifs of the TFs GATA-binding protein 3 (GATA3) and MYC-
associated factor X (MAX) in the breast cancer cell line MCF-7. HaploReg data shows that this 
SNP resides in promoter regions of lung and muscle tissues, in strong enhancer regions of 14 
tissues including HSMM and NHLF cells, and in DNase I hypersensitive sites of four tissues. 
Two active epigenetic markers (H3K4Me1 and H3K27Ac) were enriched in the interval 
containing rs1121948 in seven ENCODE cell lines (Figure 2C). We examined the effect of the 
associations of the 62 SNPs from the likelihood analysis for Signal 5 and expression of genes 
within 1 Mb of the index SNP rs11780156. We found that the risk-associated G allele of 
rs1121948 was weakly associated with decreased expression of the PVT1 gene (P=0.037, 
Supplementary Table S7). 
 
Discussion 
In this study, we conducted a fine-mapping investigation at the breast cancer susceptibility locus 
on 8q24. Among women of European ancestry, we identified four independent association 
signals represented by rs35961416, rs13281615, rs7815245 and rs11780156, respectively, and 
another suggestive one tagged by rs2033101. This discovery increases the proportion of familial 
risk of breast cancer explained by variation on 8q24 from 0.25% (due to the GWAS index SNPs 
rs13281615 in Signal 2 and rs11780156 in Signal 5) to 0.55%.  
    SNP rs7815245 (Signal 3) showed a more significant association than the previously 
GWAS-identified index SNPs rs13281615 (Signal 2) and rs11780156 (Signal 5). This SNP is 




myoepithelial cells. TF occupancy data showed that SNP rs7815245 falls within the DNA 
binding motifs for ESR1 and FOXA1, two critical DNA binding proteins for the development of 
several hormone-dependent cancers including breast cancer. Breast cancer susceptibility variants 
rs4784227 on 16q12.1 and rs2981578 on 10q26 have also been reported to modulate the affinity 
11,27
for these two transcription factors.  In addition, FOXA1 has shown a critical role in estrogen-
17,28,29
ESR1 activity and endocrine response in breast cancer cells.  These results imply that the 
association between SNP rs7815245 at Signal 3 and breast cancer risk might be mediated by 
their functional effects through these two transcription factors. The risk allele T of rs7815245 
down-regulated  expression of its downstream gene POU5F1B, which encodes a weak 
transcriptional activator highly similar to the POU class 5 homeobox 1 transcription factor and is 
30
overexpressed in prostate cancer.  However, further functional studies are needed to clarify the 
biological mechanism of this SNP in breast cancer susceptibility. 
        The most attractive candidate gene for cancer risk variants in the gene-desert 8q24 region is 
the proto-oncogene MYC, because it plays a vital role in tumorigenesis and metastasis of several 
31–33
types of cancer including breast cancer.  As a key transcription factor, MYC forms 
heterodimers with MAX, and then regulates transcription of genes involved in cell growth, and 
31
proliferation.  Aberrant MYC signaling can promote cell transformation and tumor 
32,33
progression.  Although most of the GWAS-identified SNPs on 8q24 for multiple types of 
5,34
cancers  are not mapped to the MYC genic region, they may cis-regulate nearby genes 
including MYC and its 53-kb downstream non-coding gene PVT1
5
.  For example, cancer risk-
associated variants may regulate MYC expression by forming a large chromatin loop with the 
MYC
6,26,35
 locus.  This hypothesis has been partially supported by the fact that trait-associated loci 
are frequently found to be cis
26,36,37




tissues showed a trend that rs1121948 in Signal 5 might affect MYC or PVT1 expression levels 
38
(Supplementary Table 7), consistent with a co-expression pattern.  However, the risk-increased 
alleles are associated with down-regulated gene expression of MYC or PVT1. This is inconsistent 
39–42
with overexpression of these two genes commonly observed in breast cancer tumors,  leaving 
challenges to link the risk alleles and the possible candidate gene(s) in malignancy.   
        Of the five independent association signals observed among women of European ancestry, 
only rs35961416 showed a significant association in women of African ancestry. This could be 
due to small effect size, different allele frequency, or allelic heterogeneity by race. Differences in 
GWAS findings across populations have commonly been observed for breast cancer and many 
43–45
other complex traits.  Taking the GWAS index SNP rs13281615 as an example, the risk allele 
46
frequency in women of European ancestry was 0.40.  Under an additive inheritance mode to 
detect the same per-allele effect (OR = 1.08) at P = 0.05, our Asian sample with 6,269 breast 
cancer cases and 6,624 controls (risk allele frequency of 0.53) and African American sample 
with 1,116 breast cancer cases and 932 controls (risk allele frequency of 0.44) has a power of 
0.09% and 0.1%, respectively. 
 In addition to a smaller sample size for women of Asian or African ancestry, there are 
several other limitations in this study. First, no functional laboratory experiments were conducted 
for any of the putative functional SNPs implicated in our study, preventing us from drawing a 
more definitive conclusion regarding the functionality of these variants. For example, our in 
silico analyses suggest that rs1121948 is located in binding sites of GATA3 and MAX, which 
may regulate MYC expression, but such potential interaction needs to be demonstrated 
47–50




thus it is possible that some rare variants in these loci may also contribute to the risk of breast 
cancer.  
 In conclusion, our fine mapping study identified two additional and another suggestive 
independent association signals on 8q24 among women of European ancestry, which together 
with two previous reported GWAS index signals plain approximately 0.55% of excess familial 
risk of breast cancer. In addition, our functional analyses revealed two putatively functional 
variants that can be further investigated experimentally. Our study provides additional evidence 
of the importance of common independent variants on 8q24 in breast cancer susceptibility.  
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Figure 1. Manhattan plot of overall breast cancer risk association in Europeans at the 8q24 
locus. SNPs are plotted based on their chromosomal positions (hg19) and -log10 P-values for 
univariate association. The regions spanning five independent association signals (representative 
SNP for each signal are shown in Table 1) and their highly correlated SNPs are indicated by 
dashed rectangles. 
 
Figure 2. Functional annotation of the independent signal regions. (A) Chromatin states 
across the 45.6 kb region harboring two associated signals rs13281615 and rs7815245. The top 3 
tracks show enrichment of transcription regulatory histone markers H3K4me1, H3K4me3 and 
H3K27ac from seven cell lines in ENCODE. The next 9 tracks are the chromatin state annotation 
by ChromHMM derived from 9 cell types. ChromHMM color coding is as follows: orange, 
strong enhancer; yellow, weak enhancer; light green, weak transcribed; light gray, low signal. 
The next 5 tracks show the designated histone modifications in the HMEC cell line. The last two 
tracks show the open chromatin enrichment from DNase clusters and evolutionary conservation 
measurement by PhastCons from 100 vertebrates. (B) LD structure of the region harboring the 
index SNP rs13281615 and the independent signal rs7815245 in European samples. (C) 
Chromatin states across the 58.9 kb region harboring the second index SNP rs11780156 and the 
potential underlying functional SNP rs1121948. The contents of the tracks are the same as 
described in (A). (D) LD structure of the 58.9 kb region wherein SNPs rs11780156 and 
rs1121948 lie, marked with red arrows. 
Table 1.  Identification of five independent association signals for overall breast cancer risk among women of European ancestry: a collaborative study 













Univariate Analysis   Conditional Analysis 
(hg 19) r
2















     
Signal 1 rs35961416 128213561 A/- 0.44 0.75 - 0.95(0.93-0.97) 1.3x10
-5





 128355618 G/A 0.40 0.97 - 1.11(1.08-1.13) 2.0x10
-24
  1.06(1.03-1.09) 6.6x10
-6
 
Signal 3 rs7815245 128383597 T/C 0.42 1 0.48 0.90(0.88-0.92) 1.3x10
-27
  0.94(0.91-0.96) 1.1x10
-6
 
Signal 4 rs2033101 128964222 T/C 0.19 0.95 - 1.05(1.03-1.08) 5.2x10
-5





 129194641 T/C 0.16 1 - 1.07(1.05-1.10) 4.1x10
-8
  1.07(1.04-1.10) 1.7x10
-7
 
 rs1121948 129165056 G/A 0.20 




Abbreviations: LD, linkage disequilibrium; OR, odds ratio; CI, confidence interval; MAF, minor (effect) allele frequency. 
a 




 for linkage disequilibrium with index SNP rs13281615 (0.48) and rs11780156 (0.77),respectively;  "-" indicates r
2
<0.01 with any index SNPs. 
c
 Adjusted for age, study site and principal components. 
d 
Adjusted for the other four signals, age, study site and principle components. 
e
 Independent index SNPs rs13281615 and rs11780156 from previously reported genome-wide association studies. 
 
Table 2. Association of the five independent signals with breast cancer risk by ER status among 
women of European ancestry. 
SNP 
ER+ cases (n=28,038)   ER- cases (n=7,786) P for  
Adjusted per-allele 










rs35961416 0.93(0.91-0.96) 4.8x10-7  0.97(0.93-1.01) 
0.138 0.217 
rs13281615 1.08(1.04-1.11) 3.1x10-6  1.00(0.95-1.05) 
0.971 0.032 
rs7815245 0.94(0.91-0.97) 1.6x10-4  0.96(0.91-1.01) 
0.104 0.276 
rs2033101 1.06(1.03-1.09) 1.3x10-4  1.04(0.99-1.08) 
0.140 0.307 
rs11780156 1.08(1.05-1.11) 6.6x10-7  1.06(1.01-1.12) 
0.012 0.118 
Abbreviations: ER, estrogen receptor; OR, odds ratio; CI, confidence interval. 
a Adjusted for other four independent signal, age, study site and principle components. 








Table 3. Haplotype analyses of the two independent signals in relation to breast cancer risk among women of European ancestry.


























per-allele OR per-allele OR per-allele OR
Haplotypes A/- G/A T/C T/C T/C (95% CI)
c (95% CI)c (95% CI)c
Baseline A A T C C 0.125 Reference (1.00) - 0.127 Reference (1.00) - 0.130 Reference (1.00) -






























Haplo.7 - A T C T 0.029 1.13(1.03-1.23) 0.117 0.028 1.12(1.01-1.25) 0.038 0.029 1.04(0.87-1.24) 0.654
Haplo.8 A G C C T 0.024 1.11(1.01-1.23) 0.036 0.024 1.06(0.94-1.20) 0.339 0.024 1.03(0.85-1.25) 0.758





Haplo.10 - A T T C 0.037 1.11(1.02-1.20) 0.011 0.037 1.13(1.03-1.24) 9.5×10
-3
0.037 1.05(0.90-1.22) 0.529
Haplo.11 - A C T C 0.020 1.09(0.98-1.21) 0.121 0.020 1.04(0.92-1.18) 0.510 0.021 1.27(1.05-1.53) 0.013
Haplo.12 A A C C C 0.034 1.05(0.97-1.15) 0.229 0.033 1.01(0.91-1.12) 0.877 0.035 1.09(0.93-1.28) 0.300
Haplo.13 A A T C T 0.023 1.04(0.92-1.16) 0.548 0.023 1.05(0.91-1.20) 0.494 0.023 1.11(0.90-1.37) 0.318
Haplo.14 - A T C C 0.148 1.02(0.97-1.08) 0.445 0.149 1.03(0.96-1.09) 0.447 0.153 1.03(0.92-1.14) 0.618
Haplo.15 A A T T C 0.029 0.97(0.88-1.08) 0.596 0.030 0.97(0.86-1.10) 0.654 0.030 0.96(0.80-1.16) 0.697





a SNPs1-5 represent signals rs35961416, rs13281615, rs7815245, rs2033101, and rs11780156, respectively; effect alleles are shown in bold.
b Haplotype frequency.
c Adjusted for age, study site, and principal components.
Frequencyb P c
Abbreviations: ER, estrogen receptor; OR, odds ratio; CI, confidence interval. 




Table 4.  Association of top SNPs identified in women of European and non-European ancestry with breast cancer risk 
among women of Asian (6,269 cases and 6,624 controls) and African ancestry (1,116 cases and 932 controls). 
Top SNPs Allelesa 
Univariate Analysis (Asian)   Univariate Analysis (African) 
EAF OR(95% CI)b Pb   EAF OR(95% CI)b Pb 
Identified in women of European ancestry 
 
rs35961416 A/- 0.10 1.01(0.91-1.13) 0.804 
 
0.39 0.85(0.73-0.99) 0.040 
 
rs13281615 G/A 0.53 1.02(0.97-1.08) 0.357 
 
0.44 1.02(0.90-1.16) 0.721 
 
rs7815245c T/C 0.17 0.96(0.89-1.02) 0.202  0.36 0.99(0.87-1.13) 0.908 
 
rs2033101 T/C 0.33 1.00(0.95-1.05) 0.957 
 
0.09 0.85(0.67-1.07) 0.174 
 
rs11780156 T/C 0.20 0.99(0.93-1.06) 0.842 
 
0.04 0.97(0.70-1.34) 0.838 
Identified in women of non-European ancestry 
 rs16901629 G/A 0.14 1.12(1.03-1.22) 6.6×10
-3  0.38 1.07(0.92-1.24) 0.407 
 rs974451 A/G 0.23 0.91(0.85-0.96) 1.4×10
-3  0.56 0.99(0.88-1.13) 0.915 
 rs7014860 C/A 0.24 1.14(1.03-1.25) 9.8×10
-3  0.25 1.01(0.83-1.24) 0.896 
 rs979200 C/T 0.45 1.07(1.02-1.13) 8.2×10
-3  0.67 1.09(0.95-1.24) 0.230 
 rs16901857 G/A 0.24 1.08(1.02-1.15) 6.6×10
-3  0.08 1.02(0.82-1.28) 0.841 
 rs75127456 A/C 0.10 0.89(0.81-0.97) 8.9×10
-3  0.07 0.92(0.71-1.19) 0.524 
 rs56005245 C/T 0.26 1.09(1.03-1.16) 2.5×10
-3  0.37 1.02(0.89-1.16) 0.780 
 chr8:128272219:I A/AG 0.04 1.32(1.10-1.59) 2.9×10
-3  0.12 1.04(0.83-1.32) 0.715 
 rs28392817 T/G 0.17 1.10(1.03-1.18) 7.1×10
-3  0.78 1.1(0.94-1.28) 0.237 
 rs4733807 A/G 0.12 0.89(0.82-0.96) 3.6×10
-3  0.16 0.99(0.83-1.18) 0.907 
 rs55971392 G/A 0.10 0.88(0.8-0.96) 4.5×10
-3  0.04 0.88(0.61-1.27) 0.501 
 rs35686742 C/T 0.09 0.87(0.79-0.96) 4.4×10
-3  0.03 0.91(0.62-1.32) 0.619 
 rs6988558 G/C 0.44 0.98(0.93-1.04) 0.476  0.49 0.83(0.73-0.96) 9.6×10
-3 
 rs73356177 A/G 0.05 1.05(0.93-1.19) 0.426  0.10 1.36(1.11-1.67) 2.8×10
-3 
 rs1516964 C/T 0.04 0.88(0.76-1.01) 0.072  0.09 0.67(0.51-0.89) 6.1×10
-3 
 
rs56142222 G/A 0.03 1.08(0.92-1.25) 0.351 
 
0.22 1.22(1.05-1.42) 9.8×10-3 
Abbreviations:  EAF, effect allele frequency; OR, odds ratio; CI, confidence interval. 
a Effect/reference allele; effect alleles are shown in bold. 
b Adjusted for study site and two principal components for each population. 
c Except for r2 of 0.23 and 0.43 for linkage disequilibrium between rs7815245 and the index SNP rs13281615 in Asians 
and African American, all other SNPs are not in LD with either of the index SNPs rs13281615 or rs11780156 in non-






SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure S1. Previously reported GWAS loci for various types of cancer on 
8q24 spanning 128Mb-131Mb (hg19). For each locus, originally identified variant is plotted 
based on its chromosome position and -log10 P-value from cancer risk association analysis. These 
1 2
susceptibility loci for respective cancers include rs6983267 and rs1447295,  rs16901979,  
3 4 5 6
rs16902094 and rs445114,  rs1016343,  and rs1456315  for prostate cancer; rs13281615  and 
7 8 9
rs11780156  for breast cancer; rs6983267 for colorectal cancer;  rs9642880 for Bladder cancer;  
10 11 12
rs10088218  for ovarian cancer;  rs35252396 for renal cell carcinoma;  rs4295627 for glioma;  
13 14
rs2456449 for chronic lymphocytic leukemia;  and rs2019960 for Hodgkin's lymphoma.  Note 
1 8
that rs6983267 confers risk for both prostate  and colorectal cancer.  The middle panel shows the 
LD (r
2
) between each of cancer risk-associated SNPs based on European ancestry subjects 
included in the 1000 Genomes Project (released in Mar 2012). All of these SNPs are not related 
except for two prostate cancer associated SNPs rs1016343 and rs1456315 (r
2 
= 0.29) and the 
prostate cancer associated SNP rs445114 and the breast cancer associated SNP rs13281615 (r
2 
= 
0.37). The lower panel shows genes from the NCBI RNA reference sequences and the 
highlighted region where two breast cancer susceptibility loci locate.  
Supplementary Figure S2. Regional association plots for 8q24 fine-mapping SNPs in 
Europeans. (a) Overall breast cancer risk association from univariate Logistic regression 
analysis with adjustment for age, study site and principal components. (b) Regional regression 
association plots for Signals 1-5 when other four representative SNPs are also included in the 
model. The index SNP is set as rs13281615 in Signal 2 (the purple diamond). The LD (r
2
) 
between the index SNP and other tested SNPs is computed based on European ancestry subjects 
included in the 1000 Genomes Project (released in Mar 2012). The plots are generated for SNPs 
showing P
15
 values <0.05 using LocusZoom.   
Supplementary Figure S3. Transcription factor binding annotation of the independent 
Signal 3. (A) The plot represents the ESR1 and FOXA1 ChIP-seq peaks covering the 
independent signal rs7815245 in MCF-7, TAMR and ZR751 breast cancer cell lines. The y-axis 
denotes the read per million (RPM) normalized for ChIP-seq peaks. The synopses shown to the 





study by Hurtado et al  for details. (B) The DNA sequence around the SNP rs7815245 harbors 
two DNA binding motifs, for ESR1 and FOXA1. 
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Supplementary Table 1. Summary of publically accessible ChIP-seq data for ESR1 and FOXA1 in breast cancer cells. 
Sample ID Description Cell line Experimental treatment Synopsis 
GSM631452  
[E-MTAB-223] 
E2_ER_ChIP_exp1_lane1 MCF-7 100 nM estrogen (E2) for 1h MCF7 E2 ER exp1 
GSM631453  
[E-MTAB-223] 
E2_ER_ChIP_exp1_lane2 MCF-7 100 nM estrogen (E2) for 1h MCF7 E2 ER exp1 
GSM631454  
[E-MTAB-223] 
E2_ER_ChIP_exp2_lane1 MCF-7 100 nM estrogen (E2) for 1h MCF7 E2 ER exp2 
GSM631455  
[E-MTAB-223] 
E2_ER_ChIP_exp2_lane2 MCF-7 100 nM estrogen (E2) for 1h MCF7 E2 ER exp2 
GSM631456  [E-MTAB-223] E2_ER_ChIP_exp3 MCF-7 100 nM estrogen (E2) for 1h MCF7 E2 ER exp3 
GSM631465  
[E-MTAB-223] 
E2_ER_ChIP_siNT_exp1_lane1 MCF-7 siControl transfection and 100 nM estrogen for 1 h MCF7 E2 ER siNT 
GSM631466  
[E-MTAB-223] 
E2_ER_ChIP_siNT_exp1_lane2 MCF-7 siControl transfection and 100 nM estrogen for 1 h MCF7 E2 ER siNT 
GSM631471  
[E-MTAB-223] 
FoxA1_ChIP_MCF7_full_media MCF-7 Full media 




FoxA1_ChIP_ZR751_full_media ZR751 Full media 




FoxA1_ChIP_TAMR_full_media TAMR Full media 




full_ER_ChIP_MCF7_exp1_lane1 MCF-7 Full media MCF7 full ER exp1 
GSM631481  
[E-MTAB-223] 
full_ER_ChIP_MCF7_exp1_lane2 MCF-7 Full media MCF7 full ER exp1 
GSM631482  
[E-MTAB-223] 
full_ER_ChIP_MCF7_exp1_lane3 MCF-7 Full media MCF7 full ER exp1 
GSM631483  
[E-MTAB-223] 
full_ER_ChIP_MCF7_exp2_lane1 MCF-7 Full media MCF7 full ER exp2 
GSM631484  
[E-MTAB-223] 
full_ER_ChIP_MCF7_exp2_lane2 MCF-7 Full media MCF7 full ER exp2 
GSM631494  [E-MTAB-223] MCF7_input_lane1 MCF-7 no MCF7 input 
GSM631495  [E-MTAB-223] MCF7_input_lane2 MCF-7 no MCF7 input 
GSM631496  [E-MTAB-223] ZR751_input_lane1 ZR751 no ZR751 input 
GSM631497  [E-MTAB-223] ZR751_input_lane2 ZR751 no ZR751 input 
GSM631500  [E-MTAB-223] TAMR_input TAMR no TAMR input 
 
Supplementary Table 2. Association of top SNPs with breast cancer risk (combined P value <1×10
-4


































































































































































































































































































































































































































































































rs6984136 128320138 T/C 0.04/<0.01 0.048 1.000 1.1(1.05-1.15) 1.63E- 1.12(1.07-1.18) 1.32E- 1.09(1-1.18) 5.76E- 8.09E-
05 05 02 01 
















































































































































































































































































































































































































































































rs78015822 128336740 G/A 0.24/<0.01 0.475 0.927 1.08(1.05-1.1) 3.12E- 1.08(1.06-1.11) 1.96E- 1.03(0.99-1.07) 1.05E- 1.89E-
13 11 01 02 




















































































































































































































































































































































































































































rs670725 128347157 C/A 0.94/<0.01 0.400 0.995 1.1(1.08-1.12) 5.79E- 1.11(1.09-1.14) 2.06E- 1.02(0.98-1.06) 3.58E- 3.28E-
23 19 01 05 








































































































































































































































































































































































































































chr8:128362796:I 128362796 CTTT/C 0.35/<0.01 0.716 0.980 0.93(0.92- 4.06E- 0.93(0.91-0.95) 2.28E- 0.98(0.94-1.02) 3.27E- 1.02E-
0.95) 10 08 01 02 


























































































































































































































































































































































































































































chr8:128387063:D 128387063 T/TATA 0.39/<0.01 0.373 0.971 0.9(0.88-0.92) 5.48E- 0.9(0.88-0.92) 1.38E- 0.96(0.92-0.99) 1.77E- 1.98E-
24 19 02 03 






































































































































































































































































































































































































































































rs10956413 129167185 A/C <0.01/0.56 0.248 0.985 1.05(1.03- 4.29E- 1.06(1.04-1.09) 2.04E- 1.04(1-1.09) 5.67E- 8.15E-
1.08) 06 06 02 02 
























































































































































































































































































































































































































































































rs56354710 129199352 A/T <0.01/0.55 0.222 0.878 1.07(1.04- 2.98E- 1.08(1.05-1.11) 2.32E- 1.06(1.02-1.11) 8.83E- 1.93E-
1.09) 07 07 03 01 


































































































































































































































































































































































































































































































rs10492294 129246415 C/T <0.01/0.32 0.214 0.999 1.05(1.02- 6.03E- 1.06(1.03-1.09) 1.60E- 1.03(0.98-1.07) 2.57E- 5.06E-
1.07) 05 05 01 02 












 SNP identification number from the 1000 Genomes Project. 
b
 Base position on chromosome 8  is based on the NCBI human genome build 37 from the 1000 Genomes Project. 
c




 for linkage disequilibrium with the index SNPs rs13281615 and rs11780156 computed with data of European ancestry women controls. 
e
 Effect allele frequency (EAF) is calculated with combined women controls of European ancestry. 
f
 Per allele odds ratio (OR), 95% confidence interval (CI) and significance were estimated from logistic regression, adjusted for age, study site and principal components.  
g
 Adjusted for age, study site and principal components. 
h
 Breast cancer risk estimated for ER-positive disease, adjusted for age, study site and principal components.. 
i
 Breast cancer risk estimated for ER-negative disease, adjusted for age, study site and principal components. 
j
 Hetedrogeneity test between ER-positive and ER-negative disease. 
 
Supplementary Table 3. Association of top SNPs with breast cancer risk (combined P value <0.01) in women of non-European 
ancestry. 









       
 
rs76382129 127934959 C/T 0.2 0.89 1.12(1.05-1.19) 8.3E-04 
 
rs60712131 128056174 A/T 0.15 0.99 0.89(0.82-0.95) 1.3E-03 
 
rs974451 127708294 G/A 0.23 1.00 0.91(0.85-0.96) 1.4E-03 
 
rs13272700 127734691 C/T 0.22 1.00 0.91(0.85-0.96) 1.5E-03 
 
rs6982887 127730075 A/C 0.22 1.00 0.91(0.85-0.96) 1.5E-03 
 
rs7000457 127726729 G/A 0.22 1.00 0.91(0.85-0.96) 1.6E-03 
 
rs16901917 128055813 C/T 0.14 1.00 0.89(0.82-0.96) 1.7E-03 
 
rs55708623 127751476 A/G 0.33 0.98 0.92(0.87-0.97) 1.7E-03 
 
rs2101518 127716187 T/C 0.22 0.99 0.91(0.85-0.96) 1.9E-03 
 
rs117117537 128032297 G/T 0.12 0.90 0.88(0.81-0.95) 2.0E-03 
 
rs6470466 127739184 A/G 0.22 1.00 0.91(0.85-0.97) 2.3E-03 
 
rs56005245 128113426 T/C 0.25 0.98 1.09(1.03-1.16) 2.5E-03 
 
chr8:127928795:D 127928795 A/AG 0.24 0.98 1.09(1.03-1.16) 2.6E-03 
 
rs149356055 128489905 G/A 0.02 0.70 1.33(1.10-1.60) 2.8E-03 
 
c8_pos128691265 128622083 C/T 0.09 1.00 0.87(0.79-0.95) 2.9E-03 
 
chr8:128272219:I 128272219 AG/A 0.03 0.53 1.32(1.10-1.59) 2.9E-03 
 
rs6470471 127783480 G/A 0.62 0.97 0.92(0.88-0.97) 2.9E-03 
 
rs12549369 128059230 A/T 0.15 0.98 0.89(0.83-0.96) 3.0E-03 
 
rs7815605 128590946 G/A 0.12 1.00 0.89(0.82-0.96) 3.1E-03 
 
rs76324084 129148523 C/T 0.06 0.93 1.17(1.05-1.30) 3.1E-03 
 
rs75846588 127929528 G/C 0.24 1.00 1.09(1.03-1.16) 3.2E-03 
 
rs76891459 127929542 T/G 0.24 1.00 1.09(1.03-1.16) 3.2E-03 
 
rs13259479 127675332 T/G 0.27 0.99 1.09(1.03-1.15) 3.4E-03 
 
rs12548654 127932874 G/T 0.24 0.99 1.09(1.03-1.16) 3.6E-03 
 
rs4733807 128592256 G/A 0.12 0.98 0.89(0.82-0.96) 3.6E-03 
 
rs2129544 127936351 A/G 0.24 0.99 1.09(1.03-1.15) 4.1E-03 
 
rs12550197 127935661 C/T 0.24 0.99 1.09(1.03-1.15) 4.1E-03 
 
rs35686742 128613878 T/C 0.09 0.95 0.87(0.79-0.96) 4.4E-03 
 
rs55971392 128598784 A/G 0.1 0.97 0.88(0.80-0.96) 4.5E-03 
 
rs983592 127808949 A/G 0.35 0.91 0.92(0.87-0.98) 4.6E-03 
 
c8_pos128711250 128642068 C/T 0.11 1.00 0.88(0.81-0.96) 4.7E-03 
 
rs77269231 127934542 C/T 0.24 0.98 1.09(1.03-1.15) 4.9E-03 
 
rs2171769 127798919 G/A 0.35 0.91 0.92(0.87-0.98) 5.0E-03 
 
rs12542598 127935518 T/A 0.24 0.99 1.09(1.03-1.15) 5.1E-03 
 
rs117981446 127916735 C/T 0.06 0.50 1.20(1.06-1.36) 5.3E-03 
 
rs143740159 128037636 T/C 0.13 0.97 0.89(0.83-0.97) 5.4E-03 
 
rs79831056 129148701 T/C 0.06 0.98 1.15(1.04-1.27) 5.4E-03 
 
rs116088171 129148896 A/T 0.06 0.98 1.15(1.04-1.27) 5.4E-03 
 
rs116343249 129149049 G/A 0.06 0.98 1.15(1.04-1.27) 5.4E-03 
 
rs11996839 128631622 C/T 0.11 0.98 0.89(0.82-0.97) 5.5E-03 
 
rs75742348 129148352 T/C 0.06 0.98 1.15(1.04-1.27) 5.7E-03 
 
rs79983962 129145314 C/G 0.06 0.97 1.15(1.04-1.27) 5.7E-03 
 
rs79352355 129145353 T/C 0.06 0.97 1.15(1.04-1.27) 5.7E-03 
 
rs16901905 128036579 T/C 0.14 0.98 0.90(0.83-0.97) 5.8E-03 
 
rs11985853 128631524 T/A 0.11 1.00 0.89(0.82-0.97) 5.8E-03 
 
rs11993113 128631530 T/G 0.11 1.00 0.89(0.82-0.97) 5.9E-03 
 
rs75304215 128635589 C/T 0.1 0.87 0.88(0.80-0.96) 5.9E-03 
 
rs10101587 128635755 C/T 0.1 0.87 0.88(0.80-0.96) 6.0E-03 
 
rs10086191 128635476 G/A 0.1 0.87 0.88(0.80-0.96) 6.0E-03 
 
rs10085933 128635230 G/A 0.1 0.87 0.88(0.80-0.96) 6.0E-03 
 
rs12546164 127903238 T/C 0.21 0.88 1.10(1.03-1.17) 6.1E-03 
 
rs7815310 128062896 C/T 0.15 1.00 0.90(0.84-0.97) 6.5E-03 
 
rs16901629 127672507 A/G 0.13 0.69 1.12(1.03-1.22) 6.6E-03 
 
rs16901857 127925789 A/G 0.24 0.99 1.08(1.02-1.15) 6.6E-03 
 
chr8:127754893:D 127754893 G/GTT 0.56 0.90 0.93(0.88-0.98) 6.7E-03 
 
rs76875214 128037747 G/A 0.14 0.98 0.90(0.83-0.97) 6.9E-03 
 
rs74418064 128636558 A/G 0.1 0.87 0.88(0.80-0.97) 7.0E-03 
 
rs76777631 128637525 A/G 0.1 0.87 0.88(0.80-0.97) 7.0E-03 
 
chr8:127754898:D 127754898 T/TTG 0.56 0.89 0.93(0.88-0.98) 7.0E-03 
 
rs28392817 128272220 G/T 0.17 1.00 1.10(1.03-1.18) 7.1E-03 
 
rs77446604 128635036 A/G 0.1 0.88 0.88(0.80-0.97) 7.3E-03 
 
rs78338326 128633750 A/T 0.1 0.88 0.88(0.80-0.97) 7.6E-03 
 
rs11992514 128632636 C/T 0.1 0.95 0.89(0.81-0.97) 7.6E-03 
 
rs60208962 128632585 A/C 0.1 0.95 0.89(0.81-0.97) 7.7E-03 
 
rs11774427 128593690 G/C 0.1 0.98 0.89(0.81-0.97) 7.7E-03 
 
rs79170863 128633858 G/A 0.1 0.88 0.88(0.80-0.97) 7.9E-03 
 
rs1873186 127837111 T/G 0.93 1.00 1.16(1.04-1.29) 8.0E-03 
 
rs979200 127923720 T/C 0.45 1.00 1.07(1.02-1.13) 8.2E-03 
 
rs79941908 128640038 C/T 0.09 0.82 0.88(0.79-0.97) 8.3E-03 
 
chr8:128153727:I 128153727 CT/C 0.05 0.93 1.17(1.04-1.32) 8.4E-03 
 
rs35813501 128235083 A/C 0.13 1.00 0.90(0.84-0.97) 8.7E-03 
 
c8_pos129122927 129053745 A/G 0.19 0.99 0.92(0.86-0.98) 8.8E-03 
 
rs76020024 128051923 G/A 0.13 0.97 0.90(0.83-0.97) 8.8E-03 
 
rs7003877 127760670 C/T 0.28 1.00 0.93(0.88-0.98) 8.8E-03 
 
rs75127456 128008134 C/A 0.1 0.98 0.89(0.81-0.97) 8.9E-03 
 
rs111814509 128019180 C/A 0.11 0.98 0.90(0.82-0.97) 9.2E-03 
 
chr8:128011837:D 128011837 T/TAA 0.11 0.99 0.90(0.82-0.97) 9.5E-03 
 
rs4282527 128630497 T/G 0.11 0.99 0.89(0.82-0.97) 9.6E-03 
 
rs7014860 127905188 A/C 0.22 0.36 1.14(1.03-1.25) 9.8E-03 
 
rs4314620 128630589 A/C 0.11 0.99 0.89(0.82-0.97) 9.8E-03 
 
rs10956329 127841932 C/T 0.93 1.00 1.15(1.03-1.28) 1.0E-02 
 
rs13257258 127842198 C/T 0.93 1.00 1.15(1.03-1.28) 1.0E-02 
African American 
      
 
rs73361922 129266860 A/G 0.03 0.93 1.94(1.38-2.74) 1.6E-04 
 
rs10092526 129274507 C/G 0.38 0.99 0.78(0.68-0.89) 1.9E-04 
 
rs7846242 129268140 T/C 0.39 1 0.78(0.68-0.89) 2.1E-04 
 
rs73361926 129267034 T/G 0.03 0.94 1.84(1.32-2.57) 3.2E-04 
 
rs73361943 129271296 G/A 0.05 0.97 1.59(1.21-2.10) 9.6E-04 
 
rs73361919 129266001 A/G 0.04 0.98 1.61(1.21-2.13) 1.0E-03 
 
rs73361928 129268062 G/A 0.04 0.98 1.60(1.21-2.12) 1.1E-03 
 
rs73361920 129266479 C/T 0.04 0.98 1.60(1.21-2.12) 1.1E-03 
 
rs78400768 129268242 G/A 0.04 0.98 1.60(1.21-2.12) 1.1E-03 
 
rs73361936 129269253 A/C 0.04 0.98 1.60(1.21-2.12) 1.1E-03 
 
rs112193671 129269199 C/T 0.04 0.98 1.60(1.21-2.12) 1.1E-03 
 
rs73361937 129270710 G/A 0.04 0.98 1.60(1.21-2.12) 1.1E-03 
 
rs73361940 129270736 T/A 0.04 0.98 1.60(1.21-2.12) 1.1E-03 
 
rs73361942 129270812 G/A 0.04 0.98 1.60(1.21-2.12) 1.1E-03 
 
chr8:129270768:D 129270768 C/CT 0.04 0.98 1.60(1.21-2.12) 1.1E-03 
 
rs73361944 129272494 T/C 0.04 0.98 1.60(1.21-2.12) 1.1E-03 
 
rs2142199 129266826 C/T 0.31 0.99 0.79(0.69-0.91) 1.1E-03 
 
rs4733601 129269466 G/A 0.26 1 0.79(0.68-0.91) 1.5E-03 
 
rs9642881 129324232 C/T 0.19 0.97 1.29(1.10-1.51) 1.6E-03 
 
rs73710038 128866506 A/G 0.21 0.74 0.75(0.63-0.90) 1.6E-03 
 
rs73361910 129260466 A/T 0.02 0.97 1.85(1.26-2.72) 1.8E-03 
 
rs112416472 129226925 A/C 0.02 0.99 1.84(1.25-2.71) 2.1E-03 
 
rs9643233 129322437 T/C 0.39 1 1.22(1.07-1.38) 2.2E-03 
 
rs1120501 129274183 T/A 0.31 0.99 0.80(0.70-0.92) 2.2E-03 
 
rs73356180 129228944 A/G 0.02 0.99 1.84(1.24-2.71) 2.2E-03 
 
rs73356190 129230788 A/G 0.02 0.99 1.83(1.24-2.70) 2.3E-03 
 
rs73356192 129230991 T/C 0.02 0.99 1.83(1.24-2.70) 2.3E-03 
 
rs7842861 129325699 C/G 0.39 0.99 1.21(1.07-1.37) 2.7E-03 
 
rs73356177 129224821 G/A 0.1 0.95 1.36(1.11-1.67) 2.8E-03 
 
rs4733851 129264420 G/A 0.56 0.93 0.83(0.73-0.94) 3.2E-03 
 
rs4311631 129312530 A/T 0.39 0.99 1.21(1.06-1.37) 3.3E-03 
 
rs11778971 129318011 C/G 0.39 0.99 1.20(1.06-1.36) 3.5E-03 
 
rs6996426 129312741 G/T 0.39 0.99 1.20(1.06-1.37) 3.5E-03 
 
rs7818334 128630216 A/G 0.07 0.94 0.67(0.52-0.88) 3.5E-03 
 
rs10103510 127761312 T/C 0.03 0.75 0.51(0.32-0.80) 3.5E-03 
 
rs150846373 128647523 T/C 0.03 0.79 0.56(0.37-0.83) 3.8E-03 
 
c8_pos129054328 128985146 A/T 0.05 0.52 0.62(0.45-0.86) 4.0E-03 
 
rs79746025 128628074 T/G 0.07 0.95 0.68(0.52-0.89) 4.2E-03 
 
rs116635531 128646495 A/G 0.04 0.77 0.57(0.38-0.84) 5.0E-03 
 
rs73710037 128866252 G/C 0.09 0.68 0.68(0.52-0.89) 5.5E-03 
 
rs75603024 127791799 T/C 0.03 0.8 0.50(0.31-0.82) 5.6E-03 
 
rs75082286 129019522 C/T 0.02 0.43 0.41(0.22-0.77) 5.7E-03 
 
rs79638788 129310119 T/A 0.27 0.91 1.22(1.06-1.40) 5.8E-03 
 
rs1516964 129493657 T/C 0.08 0.69 0.67(0.51-0.89) 6.1E-03 
 
rs11786536 129000416 A/G 0.04 1 0.60(0.42-0.87) 6.5E-03 
 
rs73361950 129276057 T/C 0.04 0.96 1.49(1.12-1.99) 6.8E-03 
 
rs11777546 129311776 A/G 0.35 0.98 1.19(1.05-1.36) 6.9E-03 
 
rs59367394 129328032 T/C 0.16 0.97 1.26(1.06-1.49) 6.9E-03 
 
rs4559211 129328365 T/C 0.16 0.97 1.26(1.06-1.49) 7.0E-03 
 
rs10101587 128635755 C/T 0.2 0.83 1.25(1.06-1.47) 7.3E-03 
 
rs12680661 128827465 A/G 0.15 0.89 0.77(0.64-0.93) 7.4E-03 
 
rs75304215 128635589 C/T 0.2 0.83 1.25(1.06-1.47) 7.4E-03 
 
rs11786459 129331091 T/G 0.16 0.97 1.26(1.06-1.48) 7.4E-03 
 
rs7819582 128597214 T/C 0.49 0.96 1.19(1.05-1.36) 7.4E-03 
 
rs10086191 128635476 G/A 0.2 0.83 1.25(1.06-1.47) 7.4E-03 
 
rs36121174 129170290 T/C 0.23 0.99 0.82(0.70-0.95) 7.5E-03 
 
rs10085933 128635230 G/A 0.2 0.83 1.25(1.06-1.47) 7.6E-03 
 
rs60990950 128640649 G/C 0.44 0.76 0.82(0.71-0.95) 7.7E-03 
 
rs138554988 128449097 A/G 0.12 0.68 1.34(1.08-1.67) 8.0E-03 
 
chr8:128441225:D 128441225 A/AC 0.04 0.69 0.54(0.34-0.85) 8.3E-03 
 
rs143643635 128644345 T/C 0.03 0.81 0.57(0.38-0.87) 8.7E-03 
 
rs11779126 128987768 T/C 0.03 1 0.54(0.35-0.86) 8.7E-03 
 
rs12056931 129357876 C/T 0.17 0.98 1.24(1.06-1.45) 8.8E-03 
 
rs7841519 128217961 C/A 0.1 0.69 0.72(0.56-0.92) 8.9E-03 
 
rs76437407 129360494 T/C 0.17 0.97 1.24(1.06-1.45) 8.9E-03 
 
rs115907016 127705838 C/T 0.03 0.63 0.50(0.30-0.84) 9.1E-03 
 
rs6988558 128773207 C/G 0.48 0.82 0.83(0.73-0.96) 9.6E-03 
 
rs6651248 129023645 C/T 0.81 1 0.81(0.70-0.95) 9.7E-03 
 
rs74431944 129089033 A/G 0.03 0.79 1.64(1.13-2.38) 9.8E-03 
 
rs4733590 129027695 T/C 0.81 1 0.81(0.70-0.95) 9.8E-03 
 
rs55738171 128669298 C/A 0.07 0.53 1.46(1.10-1.94) 9.8E-03 
 
c8_pos129641585 129572403 A/G 0.2 1 1.22(1.05-1.42) 9.8E-03 
 
rs74623761 129363670 G/A 0.15 0.97 1.25(1.05-1.47) 9.9E-03 
 
rs113669912 129356053 A/G 0.15 0.97 1.25(1.05-1.47) 9.9E-03 
a
 SNP identification number from the 1000 Genomes Project. 
b
 Base position on chromosome 8  is based on the NCBI human genome build 37 from the 1000 Genomes Project. 
c
 Risk/reference alleles are based on forward positive strand of the NCBI human genome build 37 from the 1000 Genomes 
Project. 
d
 Effect allele frequency (EAF) is calculated with combined women controls of European ancestry. 
e
 Per allele odds ratio (OR), 95% confidence interval (CI) and significance were estimated from logistic regression, adjusted for 
age, study site and principal components.  
 
Supplementary Table 4. Details of 154 SNPs correlated with rs13281615 at r
2
 > 0.2. 























rs283727 128313360 A G 0.24 0.0688 0.0097 1.44E-12 60131.075 2b enhancer 
rs283728 128313500 A T 0.26 0.0716 0.0097 1.89E-13 60130.7 4 enhancer 
rs4871015 128314516 G A 0.24 -0.0774 0.0098 3.49E-15 60128.34 3a Weak transcription 
rs34882299 128314913 G A 0.23 0.0639 0.0097 3.91E-11 60131.92 4 Weak transcription 
rs283704 128315582 G A 0.25 0.0726 0.0098 1.38E-13 60130.41 4 Weak transcription 
rs283705 128317450 T C 0.22 0.0749 0.0097 1.19E-14 60128.34 2b Weak transcription 
rs10107982 128318755 C T 0.25 0.0551 0.0108 3.09E-07 60133.935 5 enhancer 
rs7838810 128321202 C T 0.4 0.0665 0.0101 5.08E-11 60133.92 5 Quiescent/Low 
rs453875 128321411 A G 0.42 0.0728 0.0098 1.05E-13 60133.385 5 Quiescent/Low 
rs445114 128323181 C T 0.37 0.0614 0.0100 8.56E-10 60133.94 5 Quiescent/Low 
rs378854 128323819 T C 0.36 0.0573 0.0101 1.25E-08 60133.84 5 Quiescent/Low 
rs421094 128323874 A G 0.37 0.0597 0.0100 2.62E-09 60133.89 5 Quiescent/Low 
rs382434 128324147 T C 0.3 0.0574 0.0102 2.10E-08 60133.94 5 Quiescent/Low 
rs618477 128327641 G C 0.36 0.0614 0.0102 2.03E-09 60133.925 5 Quiescent/Low 
rs112175013 128327800 A G 0.26 -0.0848 0.0099 1.12E-17 60126.31 5 Quiescent/Low 
rs79297161 128328709 T C 0.28 0.0582 0.0106 3.97E-08 60133.93 5 Quiescent/Low 
rs11781932 128330178 T C 0.26 -0.0853 0.0099 7.74E-18 60126.15 5 Quiescent/Low 
rs11785664 128330424 C T 0.26 -0.0854 0.0099 7.14E-18 60126.125 5 Quiescent/Low 
rs56154314 128330748 A C 0.26 -0.0876 0.0100 2.90E-18 60125.48 5 Quiescent/Low 
rs13272693 128332975 A G 0.24 0.0698 0.0098 1.26E-12 60130.775 6 Quiescent/Low 
rs13272305 128333116 G A 0.21 0.0723 0.0103 2.18E-12 60130.21 5 Quiescent/Low 
rs622856 128333180 T C 0.36 0.0679 0.0104 6.12E-11 60133.81 5 Quiescent/Low 
rs622853 128333181 A G 0.37 0.0680 0.0104 6.39E-11 60133.82 5 Quiescent/Low 
rs622556 128333197 C T 0.22 0.0670 0.0097 4.42E-12 60130.81 5 Quiescent/Low 
rs452529 128333259 C G 0.22 0.0659 0.0097 1.03E-11 60131.15 5 Quiescent/Low 
rs444318 128333513 G A 0.22 0.0656 0.0097 1.26E-11 60131.225 3a Quiescent/Low 
rs606677 128334485 C T 0.21 0.0643 0.0097 3.46E-11 60131.41 5 Quiescent/Low 
rs606345 128334499 A T 0.22 0.0659 0.0097 1.04E-11 60131.155 5 Quiescent/Low 
rs2691039 128334662 G A 0.22 0.0659 0.0097 1.05E-11 60131.155 5 Quiescent/Low 
rs13256367 128334900 C A 0.41 0.0664 0.0102 5.93E-11 60133.935 5 Quiescent/Low 
rs594154 128334911 A G 0.22 0.0659 0.0097 1.06E-11 60131.165 5 Quiescent/Low 
rs594076 128334966 C G 0.22 0.0659 0.0097 1.06E-11 60131.16 5 Quiescent/Low 
rs373701 128334992 A C 0.22 0.0659 0.0097 1.06E-11 60131.16 5 Quiescent/Low 
rs437980 128335246 C A 0.22 0.0658 0.0097 1.07E-11 60131.165 5 Quiescent/Low 
rs62516012 128335526 G C 0.27 0.0536 0.0107 5.68E-07 60133.895 4 Quiescent/Low 
rs620861 128335673 A G 0.38 0.0623 0.0100 4.67E-10 60133.935 4 Quiescent/Low 
rs620808 128335714 T C 0.22 0.0697 0.0100 3.39E-12 60130.65 3a Quiescent/Low 
rs590574 128335715 G A 0.21 0.0667 0.0101 3.60E-11 60131.505 3a Quiescent/Low 
rs443053 128335796 T G 0.38 0.0626 0.0100 4.01E-10 60133.94 5 Quiescent/Low 
rs11775799 128336236 G A 0.28 -0.0880 0.0099 5.23E-19 60125.285 5 Quiescent/Low 
rs400818 128336546 C T 0.23 0.0684 0.0097 1.57E-12 60130.85 
5 Quiescent/Low 
rs78015822 128336740 G A 0.24 0.0732 0.0100 3.12E-13 60130.26 
5 Quiescent/Low 
rs74588857 128336741 T C 0.24 0.0732 0.0100 3.12E-13 60130.26 
5 Quiescent/Low 
rs34628978 128336744 A G 0.23 0.0687 0.0097 1.38E-12 60130.76 5 Quiescent/Low 
rs386883 128336871 A G 0.23 0.0686 0.0097 1.42E-12 60130.81 
5 Quiescent/Low 
rs377649 128337241 T G 0.24 0.0691 0.0097 9.42E-13 60130.675 
5 Quiescent/Low 
rs432523 128337927 T A 0.23 0.0686 0.0097 1.41E-12 60130.81 
5 Quiescent/Low 
rs430693 128338594 T G 0.23 0.0686 0.0097 1.45E-12 60130.825 
5 Quiescent/Low 
rs684254 128338693 A G 0.23 0.0686 0.0097 1.36E-12 60130.8 
5 Quiescent/Low 
rs1395287 128338702 G C 0.41 0.0670 0.0102 4.14E-11 60133.93 
5 Quiescent/Low 
rs631845 128338760 A G 0.23 0.0691 0.0097 1.04E-12 60130.665 
3a Quiescent/Low 
rs653605 128338847 T G 0.23 0.0686 0.0097 1.41E-12 60130.81 
2c Quiescent/Low 
rs432470 128339044 T C 0.33 0.0835 0.0097 1.02E-17 60128.44 
3a Quiescent/Low 
rs424281 128339426 A G 0.33 0.0838 0.0097 8.46E-18 60128.355 
5 Quiescent/Low 
rs1668875 128341103 C G 0.51 0.0789 0.0099 1.18E-15 60133.46 
5 enhancer 
rs7002712 128341612 T A 0.28 -0.0876 0.0099 7.84E-19 60125.62 
5 enhancer 
rs587948 128341680 G T 0.51 0.0774 0.0099 4.08E-15 60133.61 
5 enhancer 
rs623401 128341727 G C 0.51 0.0773 0.0099 4.45E-15 60133.62 
5 enhancer 
rs35049703 128342114 A C 0.4 0.0672 0.0101 3.03E-11 60133.895 
5 enhancer 
rs10956359 128342154 C T 0.28 0.0560 0.0106 1.35E-07 60133.935 
5 enhancer 
rs17464492 128342866 G A 0.29 0.0612 0.0107 9.44E-09 60133.88 
4 enhancer 
rs35603878 128343341 C G 0.27 0.0502 0.0118 2.23E-05 60133.28 
5 enhancer 
rs420101 128343879 A G 0.93 0.0971 0.0099 1.27E-22 60133.93 
5 enhancer 
rs7838714 128343948 C T 0.48 -0.1077 0.0099 1.18E-27 60119.735 
5 enhancer 
rs389143 128344380 T C 0.94 0.0971 0.0099 1.21E-22 60133.91 
2b enhancer 
rs688201 128344402 T G 0.93 0.0970 0.0099 1.20E-22 60133.93 
4 enhancer 
rs595821 128344410 A G 0.94 0.0975 0.0099 7.80E-23 60133.93 
4 enhancer 
rs687324 128344591 C T 0.94 0.0974 0.0099 8.55E-23 60133.925 
3a enhancer 
rs594869 128344601 C T 0.91 0.1013 0.0102 3.18E-23 60133.74 
5 enhancer 
rs594868 128344602 A G 0.92 0.0994 0.0101 5.40E-23 60133.885 
5 enhancer 
rs687279 128344624 T C 0.62 0.0790 0.0106 7.19E-14 60133.625 
4 enhancer 
rs436238 128345028 T C 0.94 0.0973 0.0099 9.94E-23 60133.91 
4 enhancer 
rs581761 128345231 T G 0.94 0.0975 0.0099 8.66E-23 60133.93 
3a Quiescent/Low 
rs673745 128345269 T C 0.94 0.0988 0.0099 2.20E-23 60133.865 
5 Quiescent/Low 
rs688937 128345381 A T 0.94 0.0980 0.0099 5.00E-23 60133.94 
5 Quiescent/Low 
rs672888 128345463 G A 0.94 0.0980 0.0099 4.69E-23 60133.94 
5 Quiescent/Low 
rs7826557 128345731 A C 0.47 -0.1057 0.0099 1.34E-26 60121.125 
5 Quiescent/Low 
rs419018 128346259 G A 0.94 0.0979 0.0099 5.03E-23 60133.94 
5 Quiescent/Low 
rs418269 128346358 A G 0.94 0.0980 0.0099 4.90E-23 60133.94 
5 Quiescent/Low 
rs385278 128347017 C T 0.94 0.0978 0.0099 5.55E-23 60133.94 
5 Quiescent/Low 
rs391640 128347124 G A 0.36 0.0526 0.0121 1.41E-05 60131.83 
5 Quiescent/Low 
rs670725 128347157 C A 0.94 0.0978 0.0099 5.79E-23 60133.94 
5 Quiescent/Low 
rs382824 128347724 G T 0.94 0.0978 0.0099 5.58E-23 60133.94 
4 Quiescent/Low 
rs383205 128347977 A G 0.94 0.0976 0.0099 6.74E-23 60133.935 
5 Quiescent/Low 
rs373616 128348062 C T 0.94 0.0975 0.0099 7.94E-23 60133.93 
5 Quiescent/Low 
rs400772 128348298 T G 0.94 0.0972 0.0099 1.13E-22 60133.9 
5 Quiescent/Low 
rs13275275 128349727 G A 0.94 0.0978 0.0099 5.92E-23 60133.935 
5 Quiescent/Low 
rs13248140 128349888 A G 0.94 0.0977 0.0099 6.49E-23 60133.935 
5 Quiescent/Low 
rs10956360 128349970 A G 0.94 0.0979 0.0099 5.32E-23 60133.94 
5 Quiescent/Low 
rs10956361 128350106 A G 0.94 0.0972 0.0099 1.08E-22 60133.895 
5 Quiescent/Low 
rs10956362 128350386 G A 0.94 0.0976 0.0099 7.00E-23 60133.93 
5 Quiescent/Low 
rs13249993 128350515 A G 0.54 0.1035 0.0098 3.48E-26 60123.33 
5 Quiescent/Low 
rs11777532 128350608 C G 0.41 -0.0975 0.0100 2.55E-22 60125.41 
5 Quiescent/Low 
rs10956363 128351773 A G 0.94 0.0969 0.0099 1.51E-22 60133.83 
5 Quiescent/Low 
rs36024485 128352205 C T 0.52 0.0670 0.0109 9.13E-10 60132.48 
3a enhancer 
rs4871782 128352234 A G 0.94 0.0971 0.0099 1.22E-22 60133.86 
3a enhancer 
rs28759353 128352363 T G 0.64 0.0780 0.0105 1.01E-13 60133.265 
4 enhancer 
rs10087810 128352730 T C 0.82 -0.0953 0.0098 2.18E-22 60133.2 
3a enhancer 
rs12541832 128353171 A C 0.64 0.0781 0.0105 9.73E-14 60133.275 
5 enhancer 
rs13262406 128353739 G A 0.65 0.0792 0.0105 4.17E-14 60133.455 
5 enhancer 
rs17465052 128354080 A G 0.48 -0.1083 0.0099 5.72E-28 60119.345 
4 enhancer 
rs13270266 128354086 G A 0.65 0.0789 0.0105 5.03E-14 60133.41 
4 enhancer 
rs10098985 128355019 T G 0.47 -0.1063 0.0099 6.23E-27 60120.755 
5 enhancer 
rs13281615 128355618 G A - 0.1004 0.0098 2.04E-24 60133.94 
5 Quiescent/Low 
rs17465283 128355824 A G 0.47 -0.1062 0.0099 7.44E-27 60120.865 
5 Quiescent/Low 
rs13256275 128356226 A G 0.4 0.0887 0.0097 6.85E-20 60127.65 
5 Quiescent/Low 
rs17465317 128356670 T C 0.52 0.1028 0.0098 8.37E-26 60123.575 
5 Quiescent/Low 
rs13267780 128357817 A G 0.48 0.0737 0.0112 3.91E-11 60133.78 
5 Quiescent/Low 
rs10447995 128357924 A G 0.52 0.1028 0.0098 8.07E-26 60123.56 
5 Quiescent/Low 
rs6999578 128358795 T C 0.47 -0.1067 0.0099 3.98E-27 60120.29 
6 Quiescent/Low 
rs7014657 128361241 G A 0.47 -0.1069 0.0099 3.58E-27 60120.195 
5 Quiescent/Low 
rs56110209 128361928 G T 0.47 -0.1069 0.0099 3.44E-27 60120.15 
5 Quiescent/Low 
rs13272866 128363367 G A 0.45 -0.1027 0.0099 2.75E-25 60122.4 
5 Quiescent/Low 
rs10097200 128363652 C T 0.44 -0.1033 0.0099 1.15E-25 60121.51 
5 Quiescent/Low 
rs7002826 128364271 C G 0.45 -0.1061 0.0099 6.11E-27 60120.105 
5 Quiescent/Low 
rs7007568 128364906 C G 0.45 -0.1058 0.0099 8.49E-27 60120.33 
5 Quiescent/Low 
rs7842494 128366570 A C 0.39 -0.0991 0.0100 3.78E-23 60123.78 
5 Quiescent/Low 
rs5022926 128366829 C A 0.45 -0.1059 0.0099 8.01E-27 60120.25 
4 Quiescent/Low 
rs10112674 128367454 G T 0.38 0.0868 0.0097 5.08E-19 60128.2 
5 Quiescent/Low 
rs9693995 128368513 T C 0.82 -0.1006 0.0098 6.45E-25 60130.775 
4 Quiescent/Low 
rs35440286 128369973 A G 0.82 0.0895 0.0100 5.15E-19 60133.66 
5 Quiescent/Low 
rs35904426 128370183 T G 0.97 0.1010 0.0099 1.43E-24 60133.315 
6 Quiescent/Low 
rs35112951 128370271 A G 0.81 0.0871 0.0101 5.22E-18 60133.325 
5 Quiescent/Low 
rs10110330 128370755 A G 0.97 0.1019 0.0099 5.83E-25 60132.665 
5 Quiescent/Low 
rs12550713 128370949 G C 0.97 0.1019 0.0099 6.00E-25 60132.695 
3a Quiescent/Low 
rs10096351 128372172 G A 0.52 0.1049 0.0098 9.86E-27 60122.225 
5 Quiescent/Low 
rs2121629 128373027 T C 0.8 -0.0970 0.0098 3.30E-23 60132.395 
5 Quiescent/Low 
rs12541305 128373756 C T 0.45 -0.1049 0.0099 2.46E-26 60120.98 
5 Quiescent/Low 
rs978683 128374117 G A 0.68 -0.0829 0.0099 5.56E-17 60133.935 
3a Quiescent/Low 
rs9297753 128375270 T C 0.45 -0.1056 0.0099 1.17E-26 60120.505 
5 Quiescent/Low 
rs9283954 128375370 T C 0.4 -0.0981 0.0100 1.05E-22 60124.405 
5 Quiescent/Low 
rs7831303 128376732 A C 0.45 -0.1057 0.0099 1.06E-26 60120.44 
5 Quiescent/Low 
rs7815100 128376801 C T 0.45 -0.1055 0.0099 1.22E-26 60120.505 
5 Quiescent/Low 
rs7835046 128376926 T C 0.39 -0.0645 0.0105 6.95E-10 60133.915 
5 Quiescent/Low 
rs4143118 128377468 G A 0.8 -0.0967 0.0098 4.24E-23 60132.485 
5 Quiescent/Low 
rs6988647 128377656 C T 0.45 -0.1053 0.0099 1.58E-26 60120.705 
5 Quiescent/Low 
rs7006882 128377667 T G 0.8 -0.0976 0.0098 1.83E-23 60132.08 
5 Quiescent/Low 
rs9692890 128377774 A G 0.4 -0.0985 0.0100 6.30E-23 60124.135 
5 Quiescent/Low 
rs9693143 128378025 T C 0.45 -0.1053 0.0099 1.48E-26 60120.67 
5 enhancer 
rs28524866 128378191 C T 0.82 -0.0946 0.0098 3.99E-22 60133.455 
4 enhancer 
rs2060775 128378626 C T 0.25 -0.0486 0.0114 2.09E-05 60133.515 
3a Weak transcription 
rs10956364 128378883 T C 0.82 -0.1005 0.0098 6.96E-25 60130.805 
6 enhancer 
rs11776330 128378963 T G 0.8 -0.0972 0.0098 2.66E-23 60132.285 
5 no data 
rs7845452 128379409 C G 0.44 -0.1028 0.0099 2.09E-25 60121.815 
5 Weak transcription 
rs16902126 128382357 G A 0.43 -0.1016 0.0099 6.97E-25 60122.43 
5 Weak transcription 
rs7815245 128383597 T C 0.45 -0.1076 0.0099 1.33E-27 60118.935 
5 enhancer 
rs2121631 128386556 G A 0.36 -0.0680 0.0107 2.02E-10 60133.895 
5 Quiescent/Low 
rs9643220 128386926 G A 0.23 -0.0505 0.0115 1.19E-05 60133.78 
5 Quiescent/Low 
rs1562430 128387852 C T 0.45 -0.1064 0.0099 4.50E-27 60119.68 
5 Quiescent/Low 
rs2392780 128388025 G A 0.43 -0.1031 0.0099 1.42E-25 60121.435 
5 Quiescent/Low 
rs7015780 128389507 T C 0.44 -0.1074 0.0101 1.55E-26 60120.21 
5 Quiescent/Low 
rs4871017 128389765 T A 0.23 -0.0499 0.0115 1.53E-05 60133.77 
5 Quiescent/Low 
rs1949810 128394313 T C 0.25 0.0498 0.0119 2.87E-05 60133.455 
6 Quiescent/Low 





 for linkage disequilibrium with the index SNP rs13281615 (Signal 2 in text) computed with data of European ancestry women controls. 
b
 Per allele effect (beta), standard error (se) and significance were estimated from univariate logistic regression, adjusted for age, study site and principal 
components.  
c
 Results from likelihood test under a glm model which includes covariates age, study site, principal components and the signal or its correlated SNP.  
d
 Score from the estimates in the Regulome database. 2b:TF binding + any motif + DNase Footprint + DNase peak; 2c: TF binding + matched TF motif + 
DNase peak; 3a: TF binding + any motif + DNase peak; 4: TF binding + DNase peak; 5: TF binding or DNase peak; 6: other functional support data. For 
details, see http://www.regulomedb.org/index. 
e
 Implied regulatory chromatin state from ENCODE data, for details see HaploReg database website 
http://www.broadinstitute.org/mammals/haploreg/haploreg.php. 
 
Supplementary Table 5. Details of 170 SNPs correlated with rs7815245 at r
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rs55753707 128285968 G T 0.25 -0.0444 0.0097 5.15E-06 60126.175 5 Quiescent/Low 
rs283718 128307082 T C 0.28 -0.0423 0.0098 1.55E-05 60125.555 4 enhancer 
rs12549518 128309591 A G 0.35 -0.0601 0.0098 7.57E-10 60126.64 5 enhancer 
rs6996866 128310155 T C 0.35 -0.0604 0.0098 6.31E-10 60126.645 3a enhancer 
rs283727 128313360 A G 0.42 0.0688 0.0097 1.44E-12 60126.685 2b enhancer 
rs283728 128313500 A T 0.44 0.0716 0.0097 1.89E-13 60126.655 4 enhancer 
rs4871015 128314516 G A 0.58 -0.0774 0.0098 3.49E-15 60126.525 3a Weak transcription 
rs34882299 128314913 G A 0.43 0.0639 0.0097 3.91E-11 60126.455 4 Weak transcription 
rs283704 128315582 G A 0.42 0.0726 0.0098 1.38E-13 60126.59 4 Weak transcription 
rs56983490 128316676 G A 0.52 -0.0778 0.0098 2.08E-15 60126.675 5 Weak transcription 
rs283705 128317450 T C 0.43 0.0749 0.0097 1.19E-14 60126.38 2b Weak transcription 
rs7006593 128317585 T A 0.52 -0.0757 0.0098 8.58E-15 60126.69 2b Weak transcription 
rs7838810 128321202 C T 0.24 0.0665 0.0101 5.08E-11 60125.6 5 Quiescent/Low 
rs453875 128321411 A G 0.23 0.0728 0.0098 1.05E-13 60123.47 5 Quiescent/Low 
chr8:128322698:D 128322698 T TA 0.53 -0.0822 0.0100 2.45E-16 60126.655 5 Quiescent/Low 
rs445114 128323181 C T 0.23 0.0614 0.0100 8.56E-10 60126.11 5 Quiescent/Low 
rs378854 128323819 T C 0.22 0.0573 0.0101 1.25E-08 60126.475 5 Quiescent/Low 
rs421094 128323874 A G 0.23 0.0597 0.0100 2.62E-09 60126.34 5 Quiescent/Low 
rs382434 128324147 T C 0.19 0.0574 0.0102 2.10E-08 60126.265 5 Quiescent/Low 
rs618477 128327641 G C 0.23 0.0614 0.0102 2.03E-09 60126.24 5 Quiescent/Low 
rs112175013 128327800 A G 0.62 -0.0848 0.0099 1.12E-17 60126.69 5 Quiescent/Low 
rs617894 128327828 G A 0.44 0.0654 0.0099 3.46E-11 60126.45 5 Quiescent/Low 
rs79297161 128328709 T C 0.28 0.0582 0.0106 3.97E-08 60126.655 5 Quiescent/Low 
rs11781932 128330178 T C 0.62 -0.0853 0.0099 7.74E-18 60126.685 5 Quiescent/Low 
rs11785664 128330424 C T 0.62 -0.0854 0.0099 7.14E-18 60126.685 5 Quiescent/Low 
rs56154314 128330748 A C 0.61 -0.0876 0.0100 2.90E-18 60126.625 5 Quiescent/Low 
rs13271897 128332878 T C 0.43 0.0617 0.0099 4.48E-10 60126.095 6 Quiescent/Low 
rs13272693 128332975 A G 0.44 0.0698 0.0098 1.26E-12 60126.68 6 Quiescent/Low 
rs13272305 128333116 G A 0.43 0.0723 0.0103 2.18E-12 60126.68 5 Quiescent/Low 
rs622856 128333180 T C 0.24 0.0679 0.0104 6.12E-11 60125.63 5 Quiescent/Low 
rs622853 128333181 A G 0.24 0.0680 0.0104 6.39E-11 60125.615 5 Quiescent/Low 
rs622556 128333197 C T 0.45 0.0670 0.0097 4.42E-12 60126.6 5 Quiescent/Low 
rs452529 128333259 C G 0.45 0.0659 0.0097 1.03E-11 60126.515 5 Quiescent/Low 
rs444318 128333513 G A 0.45 0.0656 0.0097 1.26E-11 60126.49 3a Quiescent/Low 
chr8:128334141:D 128334141 C CCT 0.4 0.0671 0.0101 3.25E-11 60126.57 5 Quiescent/Low 
chr8:128334150:D 128334150 C CTT 0.44 0.0655 0.0098 2.25E-11 60126.43 5 Quiescent/Low 
rs606677 128334485 C T 0.46 0.0643 0.0097 3.46E-11 60126.195 5 Quiescent/Low 
rs606345 128334499 A T 0.45 0.0659 0.0097 1.04E-11 60126.515 5 Quiescent/Low 
rs2691039 128334662 G A 0.45 0.0659 0.0097 1.05E-11 60126.515 5 Quiescent/Low 
rs13256367 128334900 C A 0.24 0.0664 0.0102 5.93E-11 60125.73 5 Quiescent/Low 
rs594154 128334911 A G 0.45 0.0659 0.0097 1.06E-11 60126.51 5 Quiescent/Low 
rs594076 128334966 C G 0.45 0.0659 0.0097 1.06E-11 60126.515 5 Quiescent/Low 
rs373701 128334992 A C 0.45 0.0659 0.0097 1.06E-11 60126.515 5 Quiescent/Low 
rs437980 128335246 C A 0.45 0.0658 0.0097 1.07E-11 60126.51 5 Quiescent/Low 
rs620861 128335673 A G 0.24 0.0623 0.0100 4.67E-10 60126.09 4 Quiescent/Low 
rs620808 128335714 T C 0.43 0.0697 0.0100 3.39E-12 60126.67 3a Quiescent/Low 
rs590574 128335715 G A 0.42 0.0667 0.0101 3.60E-11 60126.56 3a Quiescent/Low 
rs443053 128335796 T G 0.24 0.0626 0.0100 4.01E-10 60126.06 5 Quiescent/Low 
rs11775799 128336236 G A 0.65 -0.0880 0.0099 5.23E-19 60126.645 5 Quiescent/Low 
rs400818 128336546 C T 0.47 0.0684 0.0097 1.57E-12 60126.585 5 Quiescent/Low 
rs78015822 128336740 G A 0.45 0.0732 0.0100 3.12E-13 60126.685 5 Quiescent/Low 
rs74588857 128336741 T C 0.45 0.0732 0.0100 3.12E-13 60126.685 5 Quiescent/Low 
rs34628978 128336744 A G 0.47 0.0687 0.0097 1.38E-12 60126.595 5 Quiescent/Low 
rs386883 128336871 A G 0.47 0.0686 0.0097 1.42E-12 60126.59 5 Quiescent/Low 
rs377649 128337241 T G 0.47 0.0691 0.0097 9.42E-13 60126.62 5 Quiescent/Low 
rs432523 128337927 T A 0.47 0.0686 0.0097 1.41E-12 60126.595 5 Quiescent/Low 
rs430693 128338594 T G 0.47 0.0686 0.0097 1.45E-12 60126.59 5 Quiescent/Low 
rs684254 128338693 A G 0.47 0.0686 0.0097 1.36E-12 60126.595 5 Quiescent/Low 
rs1395287 128338702 G C 0.24 0.0670 0.0102 4.14E-11 60125.64 5 Quiescent/Low 
rs631845 128338760 A G 0.47 0.0691 0.0097 1.04E-12 60126.615 3a Quiescent/Low 
rs653605 128338847 T G 0.47 0.0686 0.0097 1.41E-12 60126.595 2c Quiescent/Low 
rs432470 128339044 T C 0.54 0.0835 0.0097 1.02E-17 60126.345 3a Quiescent/Low 
rs424281 128339426 A G 0.54 0.0838 0.0097 8.46E-18 60126.32 5 Quiescent/Low 
rs1668875 128341103 C G 0.30 0.0789 0.0099 1.18E-15 60123.61 5 enhancer 
rs7002712 128341612 T A 0.65 -0.0876 0.0099 7.84E-19 60126.66 5 enhancer 
rs587948 128341680 G T 0.29 0.0774 0.0099 4.08E-15 60123.97 5 enhancer 
rs623401 128341727 G C 0.29 0.0773 0.0099 4.45E-15 60124 5 enhancer 
rs35049703 128342114 A C 0.24 0.0672 0.0101 3.03E-11 60125.52 5 enhancer 
rs420101 128343879 A G 0.42 0.0971 0.0099 1.27E-22 60120.15 5 enhancer 
rs7838714 128343948 C T 0.94 -0.1077 0.0099 1.18E-27 60125.625 5 enhancer 
rs389143 128344380 T C 0.42 0.0971 0.0099 1.21E-22 60120.175 2b enhancer 
rs688201 128344402 T G 0.42 0.0970 0.0099 1.20E-22 60120.24 4 enhancer 
rs595821 128344410 A G 0.42 0.0975 0.0099 7.80E-23 60119.99 4 enhancer 
rs687324 128344591 C T 0.42 0.0974 0.0099 8.55E-23 60120.03 3a enhancer 
rs594869 128344601 C T 0.42 0.1013 0.0102 3.18E-23 60119.44 4 enhancer 
rs594868 128344602 A G 0.42 0.0994 0.0101 5.40E-23 60119.825 4 enhancer 
rs687279 128344624 T C 0.27 0.0790 0.0106 7.19E-14 60124.34 4 enhancer 
rs436238 128345028 T C 0.42 0.0973 0.0099 9.94E-23 60120.11 4 enhancer 
rs581761 128345231 T G 0.42 0.0975 0.0099 8.66E-23 60120.01 3a Quiescent/Low 
rs673745 128345269 T C 0.42 0.0988 0.0099 2.20E-23 60119.35 5 Quiescent/Low 
rs688937 128345381 A T 0.42 0.0980 0.0099 5.00E-23 60119.79 5 Quiescent/Low 
rs672888 128345463 G A 0.42 0.0980 0.0099 4.69E-23 60119.77 5 Quiescent/Low 
rs7826557 128345731 A C 0.95 -0.1057 0.0099 1.34E-26 60126.645 5 Quiescent/Low 
chr8:128345939:I 128345939 CCTT C 0.43 0.0980 0.0099 4.97E-23 60119.8 5 Quiescent/Low 
rs419018 128346259 G A 0.42 0.0979 0.0099 5.03E-23 60119.79 5 Quiescent/Low 
rs418269 128346358 A G 0.42 0.0980 0.0099 4.90E-23 60119.785 5 Quiescent/Low 
chr8:128346646:D 128346646 A AT 0.43 0.0983 0.0099 4.05E-23 60119.69 5 Quiescent/Low 
rs385278 128347017 C T 0.42 0.0978 0.0099 5.55E-23 60119.845 5 Quiescent/Low 
rs670725 128347157 C A 0.42 0.0978 0.0099 5.79E-23 60119.865 5 Quiescent/Low 
rs382824 128347724 G T 0.42 0.0978 0.0099 5.58E-23 60119.85 4 Quiescent/Low 
rs383205 128347977 A G 0.42 0.0976 0.0099 6.74E-23 60119.945 5 Quiescent/Low 
rs373616 128348062 C T 0.42 0.0975 0.0099 7.94E-23 60119.985 5 Quiescent/Low 
rs400772 128348298 T G 0.42 0.0972 0.0099 1.13E-22 60120.175 5 Quiescent/Low 
rs13275275 128349727 G A 0.42 0.0978 0.0099 5.92E-23 60119.885 5 Quiescent/Low 
rs13248140 128349888 A G 0.42 0.0977 0.0099 6.49E-23 60119.93 5 Quiescent/Low 
rs10956360 128349970 A G 0.42 0.0979 0.0099 5.32E-23 60119.835 5 Quiescent/Low 
rs10956361 128350106 A G 0.42 0.0972 0.0099 1.08E-22 60120.185 5 Quiescent/Low 
rs10956362 128350386 G A 0.42 0.0976 0.0099 7.00E-23 60119.965 5 Quiescent/Low 
rs13249993 128350515 A G 0.80 0.1035 0.0098 3.48E-26 60124.935 5 Quiescent/Low 
rs11777532 128350608 C G 0.83 -0.0975 0.0100 2.55E-22 60126.545 5 Quiescent/Low 
chr8:128350707:D 128350707 C CA 0.44 0.0973 0.0099 1.16E-22 60120.235 5 Quiescent/Low 
c8_pos128420230 128351048 T A 0.42 0.0977 0.0099 6.43E-23 60119.92 5 enhancer 
c8_pos128420624 128351442 C A 0.42 0.0978 0.0099 5.59E-23 60119.865 5 enhancer 
rs10956363 128351773 A G 0.42 0.0969 0.0099 1.51E-22 60120.345 5 enhancer 
c8_pos128421136 128351954 T C 0.28 0.0779 0.0105 1.09E-13 60124.725 5 enhancer 
rs36024485 128352205 C T 0.25 0.0670 0.0109 9.13E-10 60126.27 3a enhancer 
rs4871782 128352234 A G 0.42 0.0971 0.0099 1.22E-22 60120.265 3a enhancer 
rs28759353 128352363 T G 0.28 0.0780 0.0105 1.01E-13 60124.705 4 enhancer 
rs10087810 128352730 T C 0.49 -0.0953 0.0098 2.18E-22 60122.2 3a enhancer 
chr8:128352967:D 128352967 C CA 0.48 -0.0951 0.0098 2.72E-22 60122.26 5 enhancer 
rs12541832 128353171 A C 0.28 0.0781 0.0105 9.73E-14 60124.695 5 enhancer 
rs13262406 128353739 G A 0.28 0.0792 0.0105 4.17E-14 60124.44 5 enhancer 
rs17465052 128354080 A G 0.94 -0.1083 0.0099 5.72E-28 60125.305 4 enhancer 
rs13270266 128354086 G A 0.28 0.0789 0.0105 5.03E-14 60124.505 4 enhancer 
rs10095860 128354785 A C 0.32 -0.0546 0.0104 1.40E-07 60126.275 5 enhancer 
rs10098985 128355019 T G 0.96 -0.1063 0.0099 6.23E-27 60126.575 5 enhancer 
rs13281615 128355618 G A 0.45 0.1004 0.0098 2.04E-24 60118.935 5 Quiescent/Low 
rs17465283 128355824 A G 0.96 -0.1062 0.0099 7.44E-27 60126.62 5 Quiescent/Low 
c8_pos128425122 128355940 A G 0.41 -0.0872 0.0097 2.19E-19 60123.21 5 Quiescent/Low 
rs13256275 128356226 A G 0.74 0.0887 0.0097 6.85E-20 60126.625 5 Quiescent/Low 
rs17465317 128356670 T C 0.83 0.1028 0.0098 8.37E-26 60125.66 5 Quiescent/Low 
c8_pos128426042 128356860 C T 0.84 0.1046 0.0098 1.27E-26 60125.165 5 Quiescent/Low 
rs13267780 128357817 A G 0.23 0.0737 0.0112 3.91E-11 60125.405 5 Quiescent/Low 
rs10447995 128357924 A G 0.83 0.1028 0.0098 8.07E-26 60125.665 5 Quiescent/Low 
rs6999578 128358795 T C 0.97 -0.1067 0.0099 3.98E-27 60126.6 6 Weak transcription 
rs7014657 128361241 G A 0.97 -0.1069 0.0099 3.58E-27 60126.6 5 Quiescent/Low 
rs56110209 128361928 G T 0.97 -0.1069 0.0099 3.44E-27 60126.595 6 Quiescent/Low 
chr8:128362790:I 128362790 TTTC T 0.24 -0.0676 0.0108 4.05E-10 60126.465 5 Quiescent/Low 
rs13272866 128363367 G A 0.96 -0.1027 0.0099 2.75E-25 60125.97 5 Quiescent/Low 
rs10097200 128363652 C T 0.97 -0.1033 0.0099 1.15E-25 60125.9 5 Quiescent/Low 
rs7002826 128364271 C G 0.99 -0.1061 0.0099 6.11E-27 60126.59 5 Quiescent/Low 
rs7007568 128364906 C G 0.98 -0.1058 0.0099 8.49E-27 60126.47 5 Quiescent/Low 
rs7842494 128366570 A C 0.86 -0.0991 0.0100 3.78E-23 60126.5 5 Quiescent/Low 
rs5022926 128366829 C A 0.99 -0.1059 0.0099 8.01E-27 60126.38 5 Quiescent/Low 
rs10112674 128367454 G T 0.73 0.0868 0.0097 5.08E-19 60126.45 5 Quiescent/Low 
rs9693995 128368513 T C 0.55 -0.1006 0.0098 6.45E-25 60121.16 4 Quiescent/Low 
rs35440286 128369973 A G 0.40 0.0895 0.0100 5.15E-19 60123.185 5 Quiescent/Low 
rs35904426 128370183 T G 0.47 0.1010 0.0099 1.43E-24 60119.39 5 Quiescent/Low 
rs35112951 128370271 A G 0.39 0.0871 0.0101 5.22E-18 60123.855 5 Quiescent/Low 
rs10110330 128370755 A G 0.47 0.1019 0.0099 5.83E-25 60118.965 5 Quiescent/Low 
rs12550713 128370949 G C 0.47 0.1019 0.0099 6.00E-25 60118.985 3a Quiescent/Low 
rs10096351 128372172 G A 0.86 0.1049 0.0098 9.86E-27 60125.445 5 Quiescent/Low 
rs2121629 128373027 T C 0.55 -0.0970 0.0098 3.30E-23 60122.705 4 Quiescent/Low 
rs12541305 128373756 C T 0.99 -0.1049 0.0099 2.46E-26 60125.145 6 Quiescent/Low 
rs978683 128374117 G A 0.46 -0.0829 0.0099 5.56E-17 60125.635 3a Quiescent/Low 
rs9297753 128375270 T C 0.99 -0.1056 0.0099 1.17E-26 60125.695 5 Quiescent/Low 
rs9283954 128375370 T C 0.87 -0.0981 0.0100 1.05E-22 60126.21 5 Quiescent/Low 
rs7831303 128376732 A C 0.99 -0.1057 0.0099 1.06E-26 60125.97 5 Quiescent/Low 
rs7815100 128376801 C T 0.99 -0.1055 0.0099 1.22E-26 60125.98 5 Quiescent/Low 
rs7835046 128376926 T C 0.31 -0.0645 0.0105 6.95E-10 60126.675 5 Quiescent/Low 
rs4143118 128377468 G A 0.55 -0.0967 0.0098 4.24E-23 60122.8 5 Quiescent/Low 
rs6988647 128377656 C T 0.99 -0.1053 0.0099 1.58E-26 60125.46 5 Quiescent/Low 
rs7006882 128377667 T G 0.54 -0.0976 0.0098 1.83E-23 60122.4 5 Quiescent/Low 
rs9692890 128377774 A G 0.87 -0.0985 0.0100 6.30E-23 60126.36 5 Quiescent/Low 
rs9693143 128378025 T C 0.99 -0.1053 0.0099 1.48E-26 60125.735 5 enhancer 
rs28524866 128378191 C T 0.53 -0.0946 0.0098 3.99E-22 60123.4 4 enhancer 
rs10956364 128378883 T C 0.56 -0.1005 0.0098 6.96E-25 60121.255 5 Weak transcription 
rs11776330 128378963 T G 0.55 -0.0972 0.0098 2.66E-23 60122.64 5 Weak transcription 
rs7845452 128379409 C G 0.98 -0.1028 0.0099 2.09E-25 60124.575 5 Weak transcription 
rs16902126 128382357 G A 0.98 -0.1016 0.0099 6.97E-25 60123.33 5 enhancer 
rs7815245 128383597 T C - -0.1076 0.0099 1.33E-27 60126.69 5 Quiescent/Low 
rs2121631 128386556 G A 0.28 -0.0680 0.0107 2.02E-10 60126.4 5 Quiescent/Low 
chr8:128387062:D 128387062 T TTA 0.78 -0.1005 0.0106 1.60E-21 60126.2 5 Quiescent/Low 
chr8:128387063:D 128387063 T TATA 0.85 -0.1026 0.0102 5.48E-24 60126.68 5 Quiescent/Low 
chr8:128387067:D 128387067 A ATAC 0.85 -0.1039 0.0102 3.14E-24 60126.655 5 Quiescent/Low 
rs1562430 128387852 C T 0.99 -0.1064 0.0099 4.50E-27 60126.505 5 Quiescent/Low 
rs2392780 128388025 G A 0.98 -0.1031 0.0099 1.42E-25 60125.325 5 Quiescent/Low 
rs7015780 128389507 T C 0.97 -0.1074 0.0101 1.55E-26 60126.59 5 Quiescent/Low 
rs2166690 128394475 G T 0.49 -0.0876 0.0103 2.02E-17 60125.95 5 Quiescent/Low 




 for linkage disequilibrium with SNP rs7815245 (Signal 3 in text) computed with data of European ancestry women controls. 
b
 Per allele effect (beta), standard error (se) and significance were estimated from univariate logistic regression, adjusted for age, study site and principal 
components.  
c
 Results from likelihood test under a glm model which includes covariates age, study site, principal components and the signal or its correlated SNP.  
d
 Score from the estimates in the Regulome database. 2b:TF binding + any motif + DNase Footprint + DNase peak; 2c: TF binding + matched TF motif + 
DNase peak; 3a: TF binding + any motif + DNase peak; 4: TF binding + DNase peak; 5: TF binding or DNase peak; 6: other functional support data. For 
details, see http://www.regulomedb.org/index. 
e
 Implied regulatory chromatin state from ENCODE data, for details see HaploReg database website 
http://www.broadinstitute.org/mammals/haploreg/haploreg.php. 
 
Supplementary Table 6. Details of 62 SNPs correlated with rs11780156 at r
2
 > 0.2. 
 























rs12542995 129145022 T C 0.68 0.0675 0.0147 4.36E-06 60170.94 5 Quiescent/Low 
rs12676630 129145876 T C 0.68 0.0670 0.0146 4.50E-06 60170.94 5 Quiescent/Low 
rs2648829 129147911 C T 0.35 0.0634 0.0120 1.42E-07 60167.8 5 Quiescent/Low 
rs12680075 129148524 C T 0.67 0.0691 0.0147 2.71E-06 60170.88 6 Quiescent/Low 
rs2542418 129149638 C T 0.49 0.0627 0.0132 2.13E-06 60170.13 6 Quiescent/Low 
rs2648832 129150668 C A 0.26 0.0560 0.0113 6.60E-07 60167.73 3a Quiescent/Low 
rs7814495 129161453 C G 0.71 0.0690 0.0147 2.60E-06 60170.94 5 Quiescent/Low 
rs10956412 129162497 C A 0.75 0.0666 0.0135 7.58E-07 60170.86 4 enhancer 
rs12676304 129163295 C A 0.63 0.0606 0.0116 1.68E-07 60169.92 4 Quiescent/Low 
rs759651 129164288 C T 0.63 0.0603 0.0116 1.76E-07 60169.92 5 Quiescent/Low 
rs1121948 129165056 G A 0.77 0.0635 0.0122 2.01E-07 60170.61 5 Quiescent/Low 
rs1121946 129165198 G T 0.81 0.0718 0.0140 2.71E-07 60170.84 3a Quiescent/Low 
rs12675643 129165692 A T 0.63 0.0608 0.0116 1.69E-07 60169.92 2b Quiescent/Low 
rs10956413 129167185 A C 0.56 0.0518 0.0113 4.29E-06 60170.69 4 Quiescent/Low 
rs7001706 129169758 C G 0.56 0.0507 0.0112 6.08E-06 60170.75 2b Quiescent/Low 
rs16893186 129170026 C T 0.56 0.0522 0.0112 3.43E-06 60170.64 4 enhancer 
rs2608029 129170126 G C 0.37 0.0521 0.0103 4.04E-07 60168.57 5 enhancer 
rs10956414 129172633 A G 0.82 0.0708 0.0138 3.12E-07 60170.88 5 Weak transcription 
rs1875028 129173675 C G 0.56 0.0518 0.0112 3.98E-06 60170.68 3a Weak transcription 
rs7002044 129177370 A C 0.56 0.0518 0.0112 3.96E-06 60170.68 5 Weak transcription 
rs10956415 129179621 A C 0.56 0.0522 0.0112 3.34E-06 60170.63 4 enhancer 
rs1499364 129179926 G A 0.59 0.0558 0.0114 8.74E-07 60170.35 2a enhancer 
rs12546580 129180513 A G 0.59 0.0560 0.0114 8.16E-07 60170.34 4 enhancer 
rs7006455 129181367 T C 0.6 0.0567 0.0113 5.73E-07 60170.25 5 enhancer 
rs11778142 129183417 C T 0.9 0.0704 0.0135 1.99E-07 60170.95 5 Weak transcription 
rs12542202 129184555 A G 0.9 0.0696 0.0134 2.24E-07 60170.94 2b enhancer 
rs1902789 129185104 G A 0.62 0.0577 0.0113 3.62E-07 60170.17 6 enhancer 
rs72722756 129186110 C T 0.99 0.0720 0.0131 4.14E-08 60170.92 2b enhancer 
rs7825555 129186266 T A 0.62 0.0576 0.0113 3.73E-07 60170.18 5 Weak transcription 
rs28597394 129190148 G A 0.61 0.0544 0.0113 1.46E-06 60170.59 5 enhancer 
rs10956416 129190290 C T 0.62 0.0579 0.0113 3.06E-07 60170.11 5 enhancer 
rs6999335 129192584 G A 0.62 0.0574 0.0113 3.73E-07 60170.19 5 enhancer 
rs6999897 129192710 A G 0.62 0.0575 0.0113 3.67E-07 60170.19 5 enhancer 
rs10808567 129192961 T G 0.62 0.0580 0.0113 2.76E-07 60170.07 5 enhancer 
rs11780156 129194641 T C - 0.0714 0.0130 4.07E-08 60170.95 5 enhancer 
rs56152647 129195921 A G 0.62 0.0577 0.0113 3.48E-07 60170.18 4 enhancer 
rs6470608 129196570 G C 0.62 0.0578 0.0113 2.92E-07 60170.1 5 enhancer 
rs6992491 129197903 G C 0.62 0.0575 0.0113 3.62E-07 60170.2 4 enhancer 
rs55929956 129199261 A G 0.62 0.0576 0.0113 3.53E-07 60170.18 5 Quiescent/Low 
rs56354710 129199352 A T 0.55 0.0633 0.0124 2.98E-07 60169.72 5 Quiescent/Low 
rs1016578 129199566 A G 1 0.0718 0.0131 4.37E-08 60170.91 4 Quiescent/Low 
rs3802173 129199914 T G 0.62 0.0577 0.0113 2.98E-07 60170.1 5 Quiescent/Low 
rs3802172 129199915 T C 0.62 0.0577 0.0113 2.99E-07 60170.1 5 Quiescent/Low 
rs992241 129203312 C A 0.61 0.0570 0.0113 4.48E-07 60170.25 3a Quiescent/Low 
rs16902714 129203826 T C 0.61 0.0571 0.0113 4.18E-07 60170.21 5 Quiescent/Low 
rs16902715 129203857 T C 0.61 0.0573 0.0113 3.78E-07 60170.15 5 Quiescent/Low 
rs10106296 129205610 A G 0.54 0.0516 0.0110 2.86E-06 60170.49 4 Quiescent/Low 
rs7836152 129211415 A G 0.84 0.0634 0.0126 4.61E-07 60170.95 6 Weak transcription 
rs12550618 129212443 T C 0.54 0.0522 0.0111 2.59E-06 60170.49 6 Weak transcription 
rs11776408 129215220 C G 0.54 0.0522 0.0111 2.51E-06 60170.48 6 enhancer 
rs11776569 129215700 T G 0.84 0.0630 0.0125 4.23E-07 60170.95 5 enhancer 
rs11989994 129217909 T C 0.54 0.0523 0.0111 2.37E-06 60170.45 4 Quiescent/Low 
rs11997192 129218127 G A 0.84 0.0629 0.0124 4.39E-07 60170.95 4 Quiescent/Low 
rs72722788 129219611 A C 0.84 0.0631 0.0125 4.95E-07 60170.95 5 Quiescent/Low 
rs9283955 129219805 C G 0.54 0.0520 0.0110 2.44E-06 60170.44 5 Quiescent/Low 
rs1967315 129224182 A G 0.53 0.0523 0.0111 2.60E-06 60170.43 6 Quiescent/Low 
rs2909242 129224680 A C 0.34 -0.0443 0.0101 1.21E-05 60169.94 6 Quiescent/Low 
rs16902734 129225868 T C 0.32 0.0470 0.0118 7.04E-05 60170.4 4 Quiescent/Low 
rs56161112 129227921 G C 0.33 0.0478 0.0119 6.28E-05 60170.38 6 Quiescent/Low 
rs12541578 129238347 G C 0.32 0.0477 0.0119 6.34E-05 60170.37 5 Quiescent/Low 
rs12541389 129243389 T C 0.32 0.0477 0.0119 6.23E-05 60170.36 4 Quiescent/Low 




 for linkage disequilibrium with the index SNP rs11780156 (Signal 5 in text) computed with data of European ancestry women controls. 
b
 Per allele effect (beta), standard error (se) and significance were estimated from univariate logistic regression, adjusted for age, study site and principal 
components.  
c
 Results from likelihood test under a glm model which includes covariates age, study site, principal components and the signal or its correlated SNP.  
d
 Score from the estimates in the Regulome database. 2a: TF binding + matched TF motif + matched DNase Footprint + DNase peak; 2b: TF binding + any 
motif + DNase Footprint + DNase peak; 3a: TF binding + any motif + DNase peak; 4: TF binding + DNase peak; 5: TF binding or DNase peak; 6: other 
functional support data. For details, see http://www.regulomedb.org/index. 
e
 Implied regulatory chromatin state from ENCODE data, for details see HaploReg database website 
http://www.broadinstitute.org/mammals/haploreg/haploreg.php. 
 
